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Understanding the molecular mechanisms regulating cardiac cell proliferation during 
the embryonic, fetal and adult life is of paramount importance in view of developing 
innovative strategies aimed at inducing myocardial regeneration after cardiac 
damage. 
The Notch pathway plays a key role in the regulation of cardiomyocyte proliferation 
during mammalian embryonic life. Moreover, it is essentially involved in the cardiac 
regeneration process after injury in Zebrafish. Therefore, we assessed the efficacy of 
Notch pathway activation to sustain cardiac regeneration in a model of myocardial 
infarction in mice.  
During early postnatal life, cardiomyocytes exit the cell cycle. We demonstrated that 
this event is paralleled by a decrease of Notch signaling and by the establishment of 
a repressive chromatin environment at Notch target genes, characterized by 
Polycomb Group protein 2-mediated silencing. The stimulation of the Notch pathway 
through Adeno-associated virus-mediated gene transfer of activated Notch1 or of 
the soluble form of the ligand Jagged1 prolonged the capacity of cardiomyocytes to 
replicate, which correlated with an increased rate of Notch target gene expression 
and the maintenance of an open chromatin conformation at Notch target gene 
promoters. However, the same vectors were ineffective in stimulating cardiac repair 
in a model of myocardial infarction in adult mice, despite efficient transgene 
expression. We identified the molecular cause of the lack of action of Notch signaling 
stimulation in adults in the increased DNA methylation at Notch target gene 
promoters, which correlated with permanent switch off of the Notch pathway.  
Our results confirm that the Notch pathway is an important regulator of neonata 
adults, due to the permanent epigenetic modifications at the DNA level at Notch 
responsive  genes l   














HEART DEVELOPMENT AND FUNCTION 
 
The heart is the first organ to form and to become functional in the embryo during 
its development. It is a complex organ composed of different muscle and non-
muscle cell types (Fig.1): atrial/ventricular cardiac myocytes, conduction system 
cells, smooth muscle/endothelial cells of the coronary arteries and veins, endocardial 
cells, valve components and connective tissue. The major sources of precursor cells 
during heart development have been identified in cardiogenic mesoderm, cardiac 
neural crest and the proepicardial region.  
 
Figure 1. Source of the different cellular components of the heart (adapted from 
[1]). 
  
The genetic program responsible for heart development is evolutionarily conserved 
and is driven by a complex network of signaling molecules and tissue specific 
transcription factors, which control the activation of the genes responsible for heart 
morphogenesis (reviewed in [2-4]). Cardiac myocyte progenitor cells are already 







cranio-lateral mesoderm, the primary heart field, which gives rise to the cardiac 
crescent. The commitment of mesodermal cells to a cardiogenic fate strictly depends 
on the paracrine signaling between the endoderm, which secretes bone 
morphogenetic proteins (BMPs), positive regulators towards the cardiac lineage and 
the ectoderm, which secretes Wnt inhibitors [5-6]. The ultimate response to these 
molecules triggers the expression of specific sets of cardiogenic genes, which drive 
the morphogenetic events involved in heart development. In Drosophila, pro-
cardiogenic signaling involves the transcription of the homeobox gene Tinman, 
necessary to activate the transcription of Mef2, which controls the differentiation of 
the precursors toward cardiomyocytes [7]. In vertebrates, Nkx2.5, the orthologue of 
Tinman, is expressed very early; its expression is cardio-specific and is maintained 
throughout the life. However, the factor does not appear to be necessary at this 
stage for cardiomyocyte specification, while mutant Nkx2.5 embryos die later during 
development due to abnormality in heart tube morphogenesis and left ventricle 
development [8]. Tinman/Nkx2.5 cooperates with the Gata family of transcription 
factors, important gene regulators of the cardiac developmental program. The 
cardiac crescent becomes organized as the linear heart tube, consisting of an inner 
layer of endocardial cells and an outer layer of myocytes held together by a dense 
extracellular matrix known as cardiac jelly. The linear heart acquires a rightward 
spiral form through a looping process, tightly controlled by an asymmetric axial 
signaling system. At this point, the cell fate of the precursors of the four cardiac 
chambers is already genetically determined. 
Even if the genetic circuitry involved is not completely defined yet, the basic helix-
loop-helix transcription factors Hand1 and Hand2 have been identified as important 
regulators of the development of the left and right ventricular segment respectively 
[2, 4]. At this stage, a second population of cardiac progenitors of splanchnic 
mesoderm is recruited; interestingly it seems that the main difference between the 
primary and the secondary heart field progenitor population is the timing of 







transcription factors [9]. These so-called secondary heart field progenitor cells 
contribute to right ventricle, atria and outflow tract formation. Newly formed 
cardiomyocytes start to secrete the extracellular matrix, resulting in the formation of 
the cardiac cushions, rapidly colonized by endocardial cells. Subsequently, a massive 
wave of myocardial proliferation triggers the formation of cardiac trabecolae.  
The growth of each chamber results from a combinatorial signaling between cell 
layers. The endocardium secretes Neuregulins, the receptors of which are expressed 
by the myocardial layer; this signaling pathway is involved in the growth process of 
the developing ventricles [10]. At this stage, swelling of the cardiac cushion 
separates the cardiac tube into distinct chambers, causing septation.  
Precursors of the cardiac valves arise from cardiac cushions: cells of endocardial 
origin migrate into the cardiac cushions and differentiate into fibrous tissue, 
responding to a complex signaling network, regulated at some extent by TGFβ 
family members [2, 11]. Other precursor cell populations migrate at this point to 
different areas of the developing heart to contribute to its final features: cardiac 
neural crest cells give rise to the vascular smooth muscle of the aortic arch and 
great vessels; epicardial cells, derived from the proepicardium, progressively envelop 
the developing heart; coronary precursor cells contribute to the coronary 
vasculature. From the epicardium, through epithelial to mesenchymal transition, a 
population of mesenchymal cells also arises, which contributes to the development 
of connective tissue, fibroblasts and smooth muscle cells of cardiac vessels [1].  
Finally, the conduction system of the heart is essentially of myocardial origin: the 
decision of becoming conducting myocytes is regulated at the genetic level through 
the expression of a peculiar transcriptional network, while the cardiac ganglia 
innervating the conduction system are mainly derived from the neural crest [12]. 
The epicardium contributes to the conduction system through interstitial fibroblasts 
sparsely found between the mature cells of the conduction system (scheme of heart 








Figure 2. Schematic representation of heart development  (adapted from [1]). 
 
The structure of the mature heart (Fig.3) reflects its embryonic development as a 
muscular tube. The right atrium receives venous blood, which enters the right 
ventricle through the tricuspid valve. From there, the blood is then pumped by the 
ventricle through the pulmonary artery to the lungs, where it is oxygenated; the 
oxygenated blood returns to the heart in the left atrium through the pulmonary 
veins and then it passes into the left ventricle through the mitral valve, from where 
it is pumped in the arterial vascular circuit in the body. Every heartbeat originates at 
the sino-atrial node located at the junction between right atrium and superior vena 
cava. The electrical impulse is propagated through the atria to the atrioventricular 
node and from there to the ventricle.  
 







IS THE HEART A POSTMITOTIC ORGAN? 
 
During the early postnatal life, a switch takes place between myocyte hyperplasia 
and hypertrophy. In humans, after withdrawal from the cell cycle, there is almost a 
threefold increase in the diameter of cardiomyocytes [13-14]. The paradigm of the 
heart as a postmitotic organ was established in the 1950s, when the first studies 
regarding heart growth were published [15-16]. First detection of mitotic figures in 
adult cardiomyocytes dates long back [17]. In more recent years, evidences of adult 
cardiomyocyte proliferation in human and rodent samples were obtained, showing 
that the mammalian heart maintains a mitotic activity even in adult organisms, 
where DNA duplication [18] and metaphasic chromosomes were detected in heart 
sections [19]. The detected proliferation rate was very variable in different studies, 
but consistently very low [20-21]. Recently, the attempt to precisely quantify 
cardiomyocyte turnover gave very different results according to the method used: 
using 14C dating, the Frisen group reported that cardiomyocytes are renewed with a 
gradual decrease from 1% turn over annually at the age of 25 to 0.45% at the age 
of 75, therefore confirming a low proliferation rate [22]. A 20 fold higher turnover 
rate was calculated analyzing the incorporation of labeled nucleotides in 
cardiomyocytes [23], pointing to an underestimation of the number of proliferative 
myocytes in the previously reported low proliferation rates. Actually, the reported 
rate of proliferation by Bergmann and colleagues is in agreement with the known 
range of ploidy in human cardiomyocytes [24] and is consistent with the lack of 
significant regeneration after damage in the adult hearts. A variety of studies have 
identified proliferative cardiomyocytes dividing symmetrically throughout all the life 
span, albeit at a very low level; it has been proposed that the low turn-over due to 
adult cardiomyocyte proliferation is an important mechanism to maintain myocardial 







The results are quite debatable also in animal models: in rodents, the analysis of a 
variety of mitotic markers in embryonic, neonatal, and adult phase has 
demonstrated robust cardiomyocyte proliferation in embryonic life only, followed 
mainly by binucleation of myocytes in the perinatal period, superimposable to their 
exit from the cell cycle [28]. The idea of a non proliferative adult heart is in 
agreement with the results of a recent study by Porrello and colleagues, who 
reported complete myocardial regeneration achieved through formation of new 
contractile cardiomyocytes in case of apical resection of the heart in 1-day old mice, 
while the formation of a fibrotic scar was prevailing when the ventricular resection 
was performed in 7-days old mice [29]. This evidence strongly supports the 
conclusion that the mammalian heart is endowed with an endogenous regenerative 
potential in fetal and early neonatal life only.  
Discrepant results have been published regarding cardiomyocyte proliferation in the 
case of myocardial injury: Hsieh and colleagues identified an increased rate of 
cardiomyocyte proliferation after myocardial infarction in mice, possibly due to 
precursor cell proliferation [25]. A more recent study however indicated that the role 
of cardiac progenitors after injury is very limited [26]. The topic is really highly 
debated: besides the identification of the population (stem cells or differentiated 
cardiomyocytes) able to proliferate and eventually repair the heart in case of injury, 
the concept itself of the existence of a regenerative pathway in mammals still 
remains highly controversial. A recent study which did not detect any increase in the 
basal proliferation rate in case of myocardial infarction in mice have added further 
fuel to the controversy, even questioning the efforts to trigger any myocardial 
regeneration in mammals [27]. Finally, recent results by Naqvi and colleagues have 
also reopened the discussion on the proliferative potential of the postnatal heart in 
mammals, by showing that a second window of transient cardiomyocyte proliferation 
occurs post-natally in preadolescent (P15) mouse hearts, which appears to be 
regulated through the IGF-1/Akt pathway, known to modulate the early postnatal 







Although there are contrasting evidences about adult cardiomyocytes proliferation, 
what remains unquestionable is that the mammalian heart is unable to recover after 
massive cardiomyocyte loss, as in the case of myocardial infarction. Since 
cardiovascular diseases are the leading cause of mortality worldwide, among which 
ischemic heart disease is the most frequent disease condition, the strong need for 
therapies triggering cardiac regeneration still remains completely unmet. 
 
CARDIAC REGENERATION IN MAMMALS 
 
As depicted in Fig.4, cardiac regeneration has been approached in a variety of 
manners, from endogenous stem/progenitor cells proliferation stimulation to 
exogenous cell therapy, from stimulation of resident adult cardiomyocyte 
proliferation to prevention of cardiomyocyte apoptosis.   
 







Antagonizing cell death and enhancing survival pathways in cardiomyocytes after an 
ischemic event are strategies which are feasible, but showing one major constraint: 
they are useful to prevent cell death, but cannot reconstitute cardiac muscle cell 
loss, which is one of the unsolved problems occurring after myocardial infarction 
[31]. Therefore major attention has been given to strategies which are aimed at 
reconstituting the cardiomyocyte population. 
Accumulating evidences on adult cardiomyocyte division suggest that one of the 
main approaches to stimulate regeneration is to increase the number of dividing pre-
existing cardiomyocytes. This task has been pursued manipulating different key 
players of the cell cycle or developmental signals known to act on cardiomyocytes. 
These include stimulation of Cyclin D2 [32] or Cyclin A1 [33], inhibition of p38 [34-
35], stimulation of Periostin downstream signaling [36] or Neuregulin1-mediated 
ERBB2 pathway activation [37]. In vivo, some of these strategies have led to better 
functional outcomes in animal models, but the efficiency in promoting adult 
cardiomyocyte proliferation has been generally very limited, with a small number of 
mainly mononucleated adult cardiomyocytes completing cell division. Recently, 
miRNAs have been demonstrated to be an efficient, novel tool to achieve 
cardiomyocyte proliferation. Inhibition of the miR-15 family, which is involved in cell 
cycle arrest, has been shown in vivo to prompt adult cardiomyocytes to proliferate 
and improve functional outcome after myocardial infarction [38], while 
administration of miR-199a-3p and miR-590-3p were demonstrated to trigger 
cardiac regeneration, improving functional outcome after infarction and stimulating 
adult cardiomyocyte proliferation [39]. 
An alternative strategy to be considered to pursue heart regeneration is the 
formation of new myocytes from multipotent cells, resident progenitor cells 









Stem cells and progenitor cells  
Historically, among adult stem cells, bone marrow derived cells (BMC) were the first 
population of stem cells reported to possess regenerative capacity in vivo. Orlic and 
collegues identified bone marrow cells able to transdifferentiate into cardiomyocytes 
and vessels once injected into the infarcted myocardium, providing significant 
functional benefit [40]. Similar results were concomitantly reported in other studies 
[41-42]. These results, however, have later been heavily questioned by a vast part 
of the scientific community [43-44]. Given the initial enthusiasm in the field, several 
clinical trials in patients with acute myocardial infarction or ischemic heart disease 
have been performed; transplantation of different subtypes of bone marrow-derived 
cells resulted in very different outcomes. The first clinical trial in which autologous 
mononuclear bone marrow cells were transplanted into the infarcted region claimed 
that the treated patients had better functional heart parameters due to the BMC-
associated myocardial regeneration and neovascularization [45]. The subsequent 
clinical trials generated contrasting results, showing no significant improvement of 
heart function in the patients infused with autologous mononuclear bone marrow 
cells [46]. Several other trials have been performed later [47], and their results were 
collectively analyzed in 2012, reporting a modest but significant improvement of the 
left ventricular ejection fraction in the treated patients, together with a small 
beneficial effect in other left ventricular parameters [48]. More recently, other two 
clinical trials were performed, both reporting lack of effect of bone marrow 
mononuclear cell delivery [49-50].  
Taking these evidences together, considering the differences in injection system, 
bone marrow cell preparation and evaluation of functional parameters, the overall 
result is that the injection of the cells is safe and feasible, even though the beneficial 
effect is very modest, possibly due to a paracrine secretion of angiogenic or pro-
survival factors, which could stimulate cardiomyocyte survival, or perhaps resident 
stem cells proliferation, therefore exerting a beneficial action of potential interest for 







Many different groups have described the existence of a pool of self-renewing, 
cardiac resident progenitor cells (CPCs) There is no unanimous agreement on the 
markers of this population: overlapping populations expressing Sca-1 [52], c-kit [53] 
or Abcg2 [54] have been described able to differentiate towards cardiomyocytes in 
vitro. One strategy to exploit this population for therapeutic approaches is its in vitro 
expansion. Studies on the c-kit+ population, which was reported to be present in 
humans, gave rise to controversial results: in an initial study, c-kit+ cells, isolated, 
expanded in vitro, differentiated toward cardiomyocytes, were transplanted in the 
context of myocardial infarction in rodents and were reported to support 
regeneration forming news cardiomyocytes [53, 55] or acting through a paracrine 
effect [56]. In other studies no transdifferentiation of c-kit+ positive cells to 
cardiomyocytes was detected [57-58]. The SCIPIO phase I clinical trial was 
performed injecting autologous CPCs in patients with ischemic cardiomyopathy [59-
60]; the results seemed encouraging, suggesting that intracoronary infusion of these 
cells improved heart functional parameters in patients, therefore suggesting to 
proceed to a phase II study. Recently, however, the phase I study results have been 
questioned [61]. 
Another population of progenitor cells are the cardiosphere-derived cells, described 
as a population of stem cells isolated from biopsies, which can be expanded in vitro 
[62]. These cells were reported to exert beneficial effects when transplanted after 
myocardial infarction, thanks to their differentiation to new cardiomyocytes and to 
the secretion of factors exerting a beneficial paracrine effect [63]. Also in this case, 
there is controversy on the cardiomyogenic potential of these cells. One report has 
not confirmed their capacity to differentiate into cardiomyocytes and has proposed a 
fibroblast origin for these cells [64], while more recent data have indicated that their 
beneficial activity has essentially to be ascribed to their paracrine action [65]. 
Despite these controversies, cardiosphere-derived cells have been used for a clinical 








Pluripotent stem cells 
Many attempts have also been performed to differentiate embryonic stem cells 
(ESC) and, more recently, reprogrammed induced pluripotent stem cells (iPS) to 
cardiomyocytes. The latter cell type is particularly appealing for regenerative 
purposes, since ESC-based therapies would be allogeneic, therefore requiring 
immunosuppression, while iPS cells would allow autologous transplantations. Several 
groups have successfully differentiated these cells into cardiomyocytes exhibiting 
intrinsic contractile activity and expressing cardiac transcription factors, but with 
myofibrillar organization typical of early-stage cardiomyocytes, therefore resembling 
immature cells [67-70].  
In the context of an injured heart, ESC-derived cardiomyocytes were demonstrated 
to differentiate into immature cardiomyocytes, regenerate infarcted myocardium and 
achieve electromechanical integration with the surrounding tissue [71-73]. Not all 
the studies are concordant on the long term effect of the transplantation: it was also 
reported that, even in the case of graft survival, at longer time points the beneficial 
effect was not maintained [74]. Recent work by Murry and colleagues addressed the 
effect of human ESC-derived cardiomyocyte (hESC-CM) grafts in larger animal 
models. Non-human primates underwent myocardial infarction, followed by the 
injection of hESC-CMs. This study demonstrated for the first time the feasibility of 
the large-scale production of hESC-derived cardiomyocytes. The functional effect of 
the graft was evaluated, demonstrating that human derived cells provide re-
muscularization to the infracted heart, showing electromechanical coupling with the 
host cardiomyocytes and perfusion by the host vasculature. The study revealed, 
however, the onset of nonfatal ventricular arrhythmias in the grafted primates, 
pointing to the need to deeper understanding the phenomenon, in order to achieve 
safe clinical translation to patients [75].  
As far as iPS-transplantation is concerned, this now appears as a very promising 
avenue for the generation of cells capable of regeneration of various organs and 







derived cardiomyocytes can engraft in the infarcted heart and provide therapeutic 
benefic in small animal models [76]. A relevant fear that might hamper further 
development of the iPS technology is the possibility that immature, non-
differentiated iPS cells might give rise to the formation of teratomas. Indeed, a case 
of teratoma induced by the transplanted cells in the context of myocardial infarction, 
probably caused by incomplete differentiation of the cells, has been already reported 
[77].  
A final interesting approach to achieve therapeutic formation of novel 
cardiomyocytes is the direct reprogramming of fibroblasts to become 
cardiomyocytes. A first attempt was performed to differentiate fibroblasts into 
cardiomyocytes using the iPS technology with a cocktail of 14 different transcription 
factors, out of which three (Gata4, Mef2C, c-Myc) were necessary to achieve the 
reprogramming of mouse cardiac fibroblasts, showing gene expression shifting from 
a fibroblast- to a cardiomyocyte-like profile. Even if the percentage of fully 
reprogrammed cells was around 1%, the reprogrammed fibroblasts were able to 
differentiate into cardiomyocytes when transplanted into mouse hearts [78].  
Other strategies have been further applied to optimize the reprogramming: the so-
called “Yamanaka cocktail” of genes (Oct4, Sox2, Klf4, c-Myc) and the addition of 
cardiogenic factor BMP4 were demonstrated to have a higher efficiency in converting 
mouse embryonic fibroblasts to cardiomyocytes [79]. A few studies also reported 
direct reprogramming in vivo. Using genetic lineage tracing experiments, resident 
non-myocytes were demonstrated to be reprogrammed into cardiomyocyte-like cells 
by in vivo local delivery of the 3 factors described by Ieda (Gata4, Mef2c and Tbx5), 
triggering also decreased infarct size and slightly better functional outcome in 
infarcted mice [80]. The authors believe that the in vivo administration of the 
reprogramming factors, which results in functional better outcome in the case of 
myocardial infarction, could be due to the higher efficiency of reprogramming 
achieved in the heart environment, compared to a Petri dish. The authors also 







enhanced survival of cardiomyocytes, facilitated differentiation of cardiac progenitors 
or improved angiogenesis could contribute to the benefits observed upon expression 
of the reprogramming factors in the heart after myocardial infarction [81]. Finally, 
the reprogramming of cardiac fibroblasts to cardiomyocytes, both in vitro and 
directly in vivo, was also achieved using a combination of four microRNAs, which 
were able to induce direct cellular reprogramming in vitro, while the administration 
of the same microRNAs in vivo into the ischemic mouse heart results in the 
conversion of cardiac fibroblasts to cardiomyocytes [82]. Further improvement in the 
reprogramming process appears to be still needed, since often the reprogrammed 
cardiomyocytes show an immature phenotype [83] and the efficiency of the process 
is still remarkably low.  
First attempts at reprogramming human fibroblasts were recently made by 
combining various cardiac transcription factors and/or microRNAs: the 
reprogrammed fibroblasts showed some sarcomere-like structures, calcium 
transients and a cardiomyocyte-like gene expression profile [84-85].  
 
Epicardial stem cells 
Considering the fundamental role of the epicardium during heart development and 
the variety of cell types that origin from this layer, epicardial progenitor cells (EPDC) 
in the context of heart injury have also been investigated. In the adult mouse heart, 
the epicardium overlaying the infarcted area is locally disrupted. In response to the 
injury, the surrounding epicardium undergoes a transient reactivation of the 
embryonic gene program [86]. The epicardium overlaying the infarcted areas is 
therefore regenerated in 3 days after the injury. This process is also paralleled by 
the formation of a thick layer of subepicardial mesenchyme above the infarcted 
area, originated by epicardial cells undergoing epithelial-mesenchymal transition 
(EMT), which contribute predominantly to fibroblasts, to a lesser extent to the 
coronary vasculature and possibly to cardiomyocytes [86]. This evidence 







it has also been reported that epicardium-derived cell activation, stimulated by 
myocardial injury, could substantially contribute to repair of the adult heart via 
regeneration of the coronary vasculature and of the myocardium vasculogenesis in 
the presence of Thymosin β4 (Tβ4) [87]; moreover Tβ4-activated EPDCs were 
reported to transdifferentiate into new cardiomyocytes, structurally and functionally 
integrated with the resident muscle, when the Tβ4 priming was performed prior to 
myocardial infarction [88], while no effect on EPDCs was detected when Tβ4 was 
administered after the injury, where EPDCs were contributing mainly to fibroblast 
population [89-90]. Finally, these cells were also reported to contribute to the 
reduction of infarct size through stimulation of angiogenesis and secretion of 
paracrine factors which can modulate the subepicardium compartment [91]. A 
deeper understanding of the potential of epicardial population is needed in order to 
evaluate the therapeutic potential of these cells in regenerative medicine.  
 
CARDIAC REGENERATION IN ZEBRAFISH 
 
It is widely known that organ regeneration can efficiently take place in lower 
vertebrates. In particular, Zebrafish has a high regenerative capacity since in adults 
amputated or injured tissues such as fins, maxillary barbel, retina, optic nerve, spinal 
cord, brain, pancreas, kidney and heart muscle can regrow [92].  
The resection of up to 20% of the heart ventricle results in the immediate formation 
of a clot, replaced in a couple of days by fibrin deposition, followed by the 
production of new, viable and functional myocardium, reaching perfect recovery 60 
days after the heart damage (Fig.5) [93]. Three different mechanisms have been 
proposed to explain which is the cell compartment responsible for the regeneration 
process: adult, contractile, differentiated myocytes could be stimulated to massively 
re-enter the cell cycle and reform the apex; regeneration could proceed through the 







cardiomyocytes; pre-existing cardiomyocytes could undergo “de-differentiation”, 
downregulating contractile genes, in order to create a population of less 
differentiated cells, able to proliferate and re-differentiate into cardiomyocytes [94]. 
Initially, it was proposed that regeneration was triggered by progenitor cells in the 
blastema, which started to express pre-cardiac markers and contractile genes and to 
proliferate. The authors speculated that injury-related signals are insufficient to 
stimulate massive adult myocardial cell proliferation, therefore progenitor cells 
contributed to the regeneration process [95]. This mechanism has recently been 
disproved by genetic fate mapping experiments, showing that the newly formed 
cardiomyocytes originate from the adult cells, which undergo partial 
dedifferentiation, detachment one from another and disassembly of the 
cytoskeleton, with no reactivation of the fetal gene program [96]. Non myocardial 
cells play a role in the regeneration process, as they create a suitable environment 
for myocardial proliferation, expressing a variety of factors, among which Raldh2, a 
retinoic acid-synthesizing enzyme, shown to be necessary for a correct injury-
response to occur [97]. 
 
Figure 5. Schematic representation of Zebrafish heart regeneration after 







The Notch signaling pathway, through the Zebrafish orthologue Notch1b, was 
demonstrated to be involved in this heart regeneration process. As in the case of fin 
regeneration, the expression of Notch1b dramatically increases the day after the 
amputation and declines two weeks later. The Notch receptor ligand DeltaC parallels 
the expression pattern of Notch1b. The discovery that the Notch pathway is involved 
in heart regeneration was particularly interesting, since this pathway is not involved 
in the genetic program leading to heart development in Zebrafish, pointing out the 
existence of a specific regenerative genetic program [99]. In a recent study, fate 
mapping experiments demonstrated that, in the case of ventricular ablation, atrial 
cardiomyocytes transdifferentiate into ventricular myocytes upon activation of the 
Notch signaling cascade, since the block of Notch activation impedes the atrial to 
ventricular transdifferentiation [100]. Recent work has further confirmed the central 
role of the Notch pathway in the heart regeneration process. Following amputation 
of the Zebrafish ventricular apex, Notch expression is activated both in the 
epicardium and in the endocardium and suppression of Notch signaling profoundly 
impairs cardiac regeneration and induces scar formation at the amputation site; 
interestingly, the block of Notch signaling in the epicardium and endocardium 
resulted in decreased proliferation of the cardiomyocyte compartment, where Notch 
expression was not reactivated upon injury [101]. These results suggest the 
existence of a complex signaling network downstream Notch activation able to drive 












THE NOTCH RECEPTOR PATHWAY 
 
Notch receptors and ligands 
In mammals, the Notch receptor family is composed of 4 type-1 transmembrane 
proteins (Notch1, -2, -3, -4), while there is only one receptor in flies (Notch) and 
two in C. elegans (LIN-12 and GLP-1) (Fig.6). The extracellular domain is composed 
by 29 to 36 epidermal growth factor (EGF) repeats followed by a negative regulatory 
region (NRR) composed of 3 cysteine-rich Lin12-Notch repeats (LNR) and a 
heterodimerization (HD) domain. For the interaction with the signal-sending cell, 
EGF repeats 11-12 are required, while repeats 24-29 prevent the interaction of the 
receptor with its ligand on the same cell [102-103]. Many of the EGF repeats can 
bind calcium ions, thus regulating Notch affinity for its ligand and signaling efficiency 
[104-105]. The LNR motifs and the heterodimerization domain act as negative 
regulators, preventing receptor activation in the absence of the ligand. The Notch 
transmembrane domain (TMD) is followed by the intracellular domain, composed by 
a RAM motif (RBP-Jk association module) involved in the binding of Notch with the 
transcription factor CSL/RBP-Jk through a high-affinity binding module centered on a 
conserved WxP motif, followed by an unstructured region containing a nuclear 
localization signal (NLS), 7 ankiryn repeats involved in protein-protein interaction 
and an evolutionary divergent transactivation domain (TAD), which recruits 
transcriptional activators as Mastermind-like and histone acetyltransferase 









Figure 6. Structure of Notch receptors in flies, mammals and C. elegans (adapted 
from [106]). 
 
There are 5 Notch ligands in mammals: Jagged1 and -2, Delta-like1, -3, -4; in 
Drosophila they are called Serrate and Delta, and LAG-2 in C. elegans (Fig.7). They 
are type-1 transmembrane proteins sharing common features in the extracellular 
domain, composed by an N-terminal DSL (Delta/Serrate/LAG-2) motif, specialized 
EGF repeats called DOS (Delta and OSM-11-like proteins) domain involved in 
receptor binding, and EGF repeats, some of which required for the interaction with 
the Notch receptors (EGF repeats 11 and 12); only in Jagged1 and -2 there is an 
additional cysteine-rich region involved in receptor binding specificity. The short 
intracellular domain is more variable, contains a PDZ domain and is involved in 








Figure 7. Structure of Notch ligands Jagged/Serrate and Delta in flies and 
mammals (adapted from [106]). 
 
Notch signaling 
Notch protein is synthesized as a peptide of 300 kDa which undergoes glycosylation 
at different sites of the extracellular domain: the EGF repeats are glycosylated by an 
O-fucosyltransferase which adds fucose to serine or threonine residues; the O-
fucosylation sites can be further modified by N-glycans by the Fringe protein. Fringe 
glycosylation can affect the ligand-binding activity [109] and could also enhance the 
cleavage occurring in the Golgi (S1 cleavage), mediated by the Furin-convertase; in 
mammals, this cleavage leads to a heterodimeric protein with an extracellular 
subunit of 180 kDa and a transmembrane domain of 120 kDa, non covalently 
associated. The heterodimer is kept inactive through a tight interaction between the 
LNRs and the heterodimerization domain. Upon ligand binding, the receptor 
undergoes a conformational change which results in the exposure of the cleavage 
site for an ADAM protease (ADAM10, Kuzbanian or TACE, tumor necrosis factor  
converting enzyme), 12 amino acids before the transmembrane domain (S2 
cleavage) [110]. The cleaved extracellular domain of Notch bound to the ligand is 
cleared from the membrane through trans-endocytosis into the signal sending cell 
[111]. The truncated form of Notch resulting from S2 cleavage is the substrate for 







intramembrane complex composed by Presenilin, Nicastrin, PEN2 and APH1 [112]. 
γ-secretase processes Notch at two different sites, eventually leading to the release, 
into the cytosol, of the Notch intracellular domain (NICD), which is able to migrate 
to the nucleus [113-114]. In the nucleus, NICD binds CSL (CBF/RBP-Jk in mammals, 
Su(H) in flies, LAG-1 in C. elegans; I will refer to it as RBP-Jk from now onward) 
transcription factor [115]. In the absence of NICD, RBP-Jk behaves as a 
transcriptional repressor, binding to histone-deacetylases and other corepressors, 
keeping the chromatin in a transcriptional silent state [112]. It has been 
hypothesized that NICD has a stronger affinity to bind RBP-Jk compared to the 
repressors [116], but this has not been definitively proven. Another model suggests 
that NICD and the repressors compete for binding to RBP-Jk [116]. After the 
interaction with NICD, RBP-Jk is converted to an activator of transcription; the 
complex formed by NICD, RBP-Jk and MAML (Mastermind-like) recruits transcription 
factors and therefore activates transcription of the target genes, mainly the Hes 
(Hairy/Enhancer-of-split) and Hey (Hairy/Enhancer-Of-Split Related With YRPW 
Motif) families of basic helix-loop-helix transcription factors [117-118]. These 
proteins bind their target sequence on DNA as homo- or heterodimers and act by 
repressing transcription of their target genes in different ways. The binding of these 
transcription factors to their cognate binding sites can cause the recruitment of 
other corepressors, such as Groucho, which can recruit histone deacetylases, 
therefore causing transcriptional repression through alteration of local chromatin 
structure; alternatively, they can directly bind to other bHLH factors forming non 
functional heterodimers [119-120]. Moreover, the NICD-RBP-Jk complex is able to 
directly activate transcription of several targets, such as Cyclin D1, Cyclin D3, p21, 
glial fibrillary acidic protein, Myc, Nodal, PTEN, EphrinB2, smooth muscle actin. 
Interestingly, several of the genes regulated by Notch have a role in the 
maintenance of a proliferative status [119, 121]. After activation of target gene 
transcription, NICD is rapidly degraded: MAML couples the activator role with the 







of MAML-SKIP-RBP-Jk can recruit the nuclear kinase CycC/CDK8 which 
hyperphosphorylates Notch TAD and PEST domains [122-123]; the phosphorylated 
PEST domain is recognized by the ubiquitin-ligase Fbw7/Sel10, resulting in NICD 
ubiquitin-mediated proteasomal degradation [124-126]. Moreover, acetylation has 
been demonstrated to regulate the stability of the NICD: in endothelial cells, Sirt1, a 
member of class III deacetlyases, was discovered to deacetylate and therefore 
destabilize NICD, triggering its degradation, therefore antagonizing the 
establishment of the transcriptional activator complex [127]. 
Recent evidence suggests that endocytosis can modulate Notch trafficking, and 
therefore its activity. In Drosophila, mutants having defects in endocytosis, 
recycling, vesicular sorting or multivesicular body formation show defects in Notch 
signaling [128-129]. A typical way of regulation of receptor internalization is protein 
monoubiquitination, which can target several residues in the Notch intracellular 
domain. HECT-type E3 ubiquitin ligase Nedd4 and Itch in mammals (Suppressor of 
Deltex in Drosophila) can act on NICD as negative regulators. These proteins are 
involved in a regulatory mechanism to prevent inappropriate ligand-independent 
activation of Notch signaling, targeting NICD to the lysosomal degradation pathway 
[130-131]. Besides the involvement of the intracellular trafficking machinery in 
keeping Notch inactive, endocytosis could also have an active role in NICD release 
and signaling. Deltex, a ring finger-type ubiquitin ligase, is thought to counteract the 
effect of Nedd4 and Itch, positively regulating Notch signaling; the factor promotes 
Notch sorting from the endosomal compartments, escaping the lysosomal 
degradation [132-133]. Moreover, Notch monoubiquitination followed by 
endocytsosis is an absolute requirement for γ-secretase to process the receptor. 
Actually, the initial paradigm of the γ-secretase complex acting on the cell surface 
has been radically revised, since the multi-subunit protease complex has been 
visualized embedded in the membranes of the endocytic vesicles, consistent with the 
evidence showing that it has an optimal activity at a low pH, as it is in the endocytic 







protecting the cell from accidental firing of the Notch pathway: since very little 
amount of NICD is required to activate the downstream pathway, this could be 
generated in a ligand independent manner; the continuous ubiquitination and 
degradation of the receptors at the cell surface could be a way to regulate the 
steady-state level of the Notch protein [130]. The possible role of endocytosis in the 
control of the ligands has also been investigated, since E3 ubiquitin-ligases 
Neuralized and Mind Bomb were found to be required for ligand internalization, 
causing higher activity of the ligands on the cell surface [135-136]. Interestingly, the 
Notch extracellular domain undergoes trans-endocytosis into the ligand-expressing 
cells, dissociating from the transmembrane domain which undergoes further 
processing [137]. Several hypotheses have been proposed to explain the link 
between ubiquitination, endocytosis and ligand activity: ligand endocytosis could 
generate a pulling force on the extracellular domain of the Notch receptor, therefore 
triggering the exposition of the cleavage site for ADAM proteases; ligand 
ubiquitination could promote its clustering and therefore a more robust Notch 
activation, or the trafficking in the endocytic compartment could allow post-
translational modifications on the ligands improving their activity [138] (schematic 








Figure 8. Notch trafficking and signaling pathway (adapted from [139]). 
 
Notch function 
Notch signaling is highly evolutionary conserved and plays a crucial role in the 
embryonic development of flies, worms and mammals. Its signaling pathway 
regulates many processes of cell fate decision; in the context of binary cell fate 
decision, Notch regulates lateral inhibition between adjacent cells, which means that 
a population of cells with equivalent developmental potential will signal to each 
other through inhibitory reciprocal Notch signaling. By the amplification of 
differences in the expression levels of either ligand or receptor within the cell 







feedback regulatory loops, therefore inhibiting the neighboring cells to adopt the 
same fate using Notch signaling [140-143] (Fig. 9A). Another case of binary cell 
fate occurs when both sister cells express ligand and receptor but, due to 
asymmetric segregation of cell fate determinants which can negatively regulate 
Notch signaling occurred prior to mitosis, the signal is polarized and the cells 
undergo different fates. One of the most important Notch-inhibitory factors is Numb, 
a phosphotyrosine binding domain adaptor protein able to bind Notch and to prevent 
its activation promoting the receptor degradation (Fig.9B) [142, 144-145].  
Notch signaling is also involved in the boundary specification through inductive 
signaling. This mechanism of signaling results in the creation of a new cell type after 
cell-cell interactions at the boundary between distinct cell populations (Fig.9C) 
[142, 146-147]. 
Notch exerts a pivotal role in the maintenance of stem cell populations. In order to 
maintain tissue homeostasis, within a population of stem cells, some have to 
undergo differentiation, while others have to maintain the stemness features. This is 
achieved by asymmetric cell division mediated by Notch signaling in many embryonic 
and post-embryonic stem cell compartments (Fig.9D) [112, 148-149]. 
 
Figure 9. Binary cell fate decision (A and B), inductive signaling (C) and stem cell 








More in detail, the importance of Notch signaling in the stem cell context has been 
widely reported in the nervous system, in Drosophila and in mammals. In 
Drosophila, the Notch signaling is responsible for the fate decision of individual cells 
among an equipotent cluster in the ectoderm, specified to become neuronal 
progenitors [150]. During embryonic development in mice, Notch stimulates 
precursor cell proliferation and inhibits neural differentiation promoting glial cell fate, 
while later it stimulates differentiation of astrocytes and inhibits terminal 
differentiation to oligodendrocytes [151]. In adults, it exerts a fundamental role in 
maintaining the stem cell pool present in the subventricular zone and in the 
subgranular zone of the brain. Here, it regulates the cell cycle exit of neural stem 
cells. Blocking Notch results in the exhaustion of the stem cell pool, with an 
increased differentiation into transient amplifying cells and neurons [152-153]. This 
mechanism might exert a role in the expansion of the neural stem cell pool after 
injury [154].  
In the intestine, stem cells reside in the Lieberkühn crypts. Here, Notch plays two 
independent roles. It regulates stem cell proliferation, since its activation triggers the 
amplification of stem/progenitor cell pool through the action of its target gene Hes1 
which blocks the expression of cyclin dependent kinase inhibitors [151, 155]. 
Moreover, it inhibits the differentiation toward secretory cells and favors the 
differentiation toward the absorptive phenotype via the negative regulation on the 
transcription factor Atoh1, which promotes secretory cell fate commitment [156-
157]. 
During muscle development, a pool of progenitors exit from the cell cycle and 
undergo differentiation expressing specific transcription factors and forming 
multinucleated myotubes. Satellite cells expressing the Pax7 transcription factor are 
localized adjacent to muscle fibers under the basal lamina, where they remain 
quiescent. This compartment is crucial in the regenerative process after injury, since 
satellite cells are driven back into the cell cycle and induce myotube proliferation. In 







myofiber formation, therefore suggesting that Notch activation blocks differentiation 
[158-159]. Loss of Notch signaling is accompanied by the loss of the satellite cell 
population since the pool of progenitors undergoes exhaustion [160]. Moreover, the 
satellite cells fail to assume the correct position, pointing to a role of Notch signaling 
also in the homing of stem cells to the correct niche [161]. In the adult, Notch 
pathway was demonstrated to be active in quiescent satellite cells, where it probably 
represses the key transcription factor necessary for terminal differentiation [162-
163]. In the case of injury, Notch is down-regulated and the satellite cells exit from 
the quiescent state to differentiate and contribute to regeneration [164].  
Finally, Notch signaling has been demonstrated to play a pivotal role in 
hematopoietic stem cell compartment in the embryo, where it is essential for 
generating hematopoietic stem cells (HSCs) from endothelial cells in the aorta-
gonad-mesonephros regions [165]. In the adult, the role of Notch is more 
controversial. Notch signaling has been reported to affect self-renewal, proliferation 
and differentiation of adult HSCs, since the treatment with its ligand increases HSC 
expansion in vitro [166-167] and overexpression of active Notch preserves/expands 
hematopoietic progenitors in vivo [168-169]. Opposite to these results, several 
genetic studies could not identify any crucial role for Notch signaling in HSC 
maintenance or proliferation [170-171], supporting the idea that it is not necessary 
for homeostasis under steady-state conditions, while it is a potent tool to expand 
HSCs in vitro. 
During somitogenesis, Notch also regulates temporal synchronization of the 
development of a group of cells: expression of the downstream gene Hes1 oscillates 
and Notch, while not triggering the oscillation itself, controls the synchronization of 
the oscillating signals [172-173].  
 
The role of Notch during heart embryogenesis and in the adult life 
Notch signaling exerts different important roles during cardiac morphogenesis. In 







differentiation towards the cardiomyocyte fate. In different models, such as 
Xenopus, chick embryo or mouse embryonic stem cells, the Notch pathway is able to 
inhibit cardiac differentiation and myocardial gene expression, blocking mesodermal 
commitment and cardiac differentiation [174-177]. Furthermore, expression of 
activated Notch in cardiac mesoderm leads to abnormal morphogenesis due to 
impaired cardiomyocyte differentiation and hyperplasia of the atrioventicular 
cushions [178]. Since Notch is involved in binary fate decision, prevention of 
cardiogenic commitment could result in commitment to another lineage. Indeed, 
embryonic stem cells receiving a positive Notch signal undergo neurectodermal 
transition and neural specification and become incapable of adopting a cardiogenic 
fate [179-180]. The exact mechanism by which Notch inhibits cardiogenesis is not 
completely defined. Notch target Hey transcription factors are able to block cardiac 
gene transcription either interacting (and thus inhibiting) the cardiac activator Gata4 
or its target genes or binding the Gata4 responsive promoters [181-182]. Moreover, 
Notch can inhibit Mef2C, which marks the cardiac and skeletal muscle lineages 
during mouse embryogenesis [162], by either physically binding to it thus impeding 
its transcriptional ability, or competing for members necessary to form the Mef2C 
transcriptional complex [183]. During cardiac development, different Notch receptors 
are expressed with a distinct local and temporal pattern: Notch1 and -2 are mostly 
expressed in the developing heart, Notch3 is restricted to smooth muscle and 
Notch4 to the endothelium of the vascular system [184-185]. The ligands also have 
a , in the ventricular trabecolae and in the atrial myocardium, while Delta-like1 and 
Delta-like4 are expressed respectively in the endocardium and in the cardiac 
crescent and later in the ventricular endocardium [186]. Notch and its ligand are 
highly expressed in the non-myogenic dorsolateral domain of the primary heart field, 
where they act by suppressing cardiogenesis [174]. Loss of function studies have 
demonstrated that Notch is not necessary in the first phases of heart development, 
such as heart field specification and induction of cardiac mesoderm, since complete 







first defect linked to Notch impaired signaling is the random looping of the heart 
[188]. Defective Notch signaling also results in defective EMT during the formation 
of cardiac cushions. This process is essential for the correct development of the 
endodermal cardiac cushions, from where cardiac valves and atrial and ventricular 
septa will develop. Notch1 mutants show a defective induction of EMT, with very few 
migrating cells, lacking mesenchymal morphology [189-190]. The effect of Notch 
signaling in this process is probably due to Notch target genes, which are able to 
regulate the expression of specific metalloproteases required for cell migration and 
to the Notch-mediated negative regulation of cadherin expression, enabling the cells 
to invade the cardiac jelly [189-190]. During ventricular trabeculae formation, 
Notch1 is expressed in the endocardium and triggers cardiomyocyte proliferation 
through two different pathways: it stimulates the production of Neuregulin1 by the 
endocardium, which allows the transition of primitive myocardial epithelium to 
trabecular and compact myocardium, and it stimulates BMP10 production in 
cardiomyocytes, which positively regulates their proliferation [191]. The importance 
of the Notch pathway in cardiac morphogenesis is highlighted by the strong 
phenotype of the gain- and loss-of function mutants of the several key molecules of 
the pathway as well as by the features of the Alagille syndrome, a human autosomal 
disorder characterized by hepatic, cardiac, skeletal and eye malformation due to 
Jagged1 mutation. In the cardiovascular system, the abnormalities include 
ventricular septal defects and hypetrophy of the right ventricle due to underlying 
pulmonary stenosis [192]. In addition, Notch can also control differentiation of 
committed mesodermal progenitors and of cardiac precursor cells into 
cardiomyocytes, reinforcing the conclusion that the Notch pathway is able to control 
cardiogenesis at multiple steps of the differentiation process, from the mesodermal 
versus neuroectodermal commitment to myocyte differentiation and proliferation 
[178-179, 193]. 
In the adult heart, several members of Notch family are expressed at different levels 







cardiomyocytes [186]. It is mainly involved in the maintenance of adult heart tissue 
integrity. Given the role of Notch in preserving the stem cell pool in several tissues, 
Notch has been hypothesized to play an important role in cell-to-cell contact 
signaling between accessory cells and cardiac precursors in putative stem cell 
niches. In particular, it has been proposed that Notch could be involved in keeping 
the precursor population quiescent, while maintaining the proliferation and 
expansion of undifferentiated cardiac precursors cells, eventually leading them from 
the immature phenotype to the compartment of amplifying myocytes [194-195], 
also regulating their proliferation and expansion [196]. 
Several studies have analyzed the role of the Notch signaling in vivo, in the context 
of cardiac regeneration, reporting a variety of pro-regenerative roles. In a model of 
myocardial injury, Notch signaling was reported to promote cardiomyocyte survival 
[197] and contribute to protective signaling, interacting with the c-Met/Akt pathway 
[198]. It was also reported to inhibit excessive fibrosis in a model of myocardial 
infarction [197] and of pressure overload, through activation of Notch signaling in 
heart stromal cells [199]. In a model of aortic constriction, it could play a role in the 
mobilization of epicardial cells, which contribute to the resolution of fibrosis; in 
addition, these cells also display a modest differentiation potential towards 
cardiomyocytes [200]. 
Finally, Notch has also been proposed to play a role in the mobilization of different 
population of stem cells, including bone marrow-derived stem cells in the case of 
myocardial infarction [201], and cardiac precursor cells [194, 199, 202]. 
Several reports have assessed the role of Notch in the tuning of cardiomyocyte 
proliferation. Reports from our laboratory have shown that Notch1 drives 
proliferation and expansion of neonatal rat cardiomyocytes [196]. Moreover Notch 
ICD was reported to activate Cyclin D1 transcription and also to promote its nuclear 
localization, therefore stimulating cardiomyocyte cell cycle progression [203], 
although recent evidence has shown incomplete cardiomyocyte proliferation [197]. 







through its target gene Hey2, the pro-hypetrophic activity of Gata4. Therefore, 
Notch might maintain cardiac tissue homeostasis by limiting the extent of the 
cardiac hypertrophic response [181-182, 204].  
 
EPIGENETIC CONTROL OF GENE EXPRESSION 
 
In eukaryotic cells, nuclear DNA is wrapped around proteins to form the chromatin. 
The primary protein components of chromatin are histones, assembled in octamers 
to form nucleosomes. This structure ensures chromatin compaction and it can 
undergo many modifications regulating most of DNA-related processes, such as 
transcription, recombination, DNA repair, replication. The modifications can be 
covalent modifications of the histones, modulation of DNA accessibility through 
chromatin complexes called chromatin remodelers, or modification on the DNA itself 
by the addition of methyl groups on the cytosines in the context of CpG 
dinucleotides. Given the complexity of the topic, in this introduction I will mainly 
describe the chromatin modifications impacting on transcription.  
Histone modifications  
Chromatin structure is highly complex and impressively dynamic. The nucleosome 
and its histone core, which were once thought to be static and highly stabilized by 
the 14 non-covalent bonds occurring between DNA and histones, actually play an 
integral role in directing some elements of transcriptional specification. The histone 
octamers forming nucleosomes are characterized by 15-30 amino-terminal residues 
which protrude from the nucleosome to form the so-called “histone tails” [205]. 
More than 60 different residues mainly residing in the histone tails have been 
demonstrated to be modified by covalent binding of various functional groups. 
The most common additions are acetylation, methylation, phosphorylation and 
ubiquitination of residues, which can act combinatorially, according to the so-called 







modifications influence chromatin are the disruption of the contacts between 
nucleosomes and DNA, since many modifications result in the change of the net 
charge of the nucleosome and in the loosening of the coil, and the recruitment of 
non-histone proteins, which can combinatorially bind to the modified histones 
(reviewed in [207]).   
Histone acetylation  
Histone acetylation is a highly dynamic process known since the 1960s [208]. The 
class of enzymes responsible for histone acetylation are the Histone Acetyl 
Transferases (HATs): they utilize AcetylCoA as a cofactor to transfer an acetyl group 
to the ε-amino group of lysine, therefore neutralizing its positive charge. HATs are 
divided into 2 families, type-A and type-B HATs. Type-B HATs are mainly 
cytoplasmic and are able to acetylate newly synthesized histones (K4 on histone 3 
and K12 on histone 4), prior to their assembly to form the nucleosome. Type-A HATs 
are divided into 3 subfamilies according to their sequence homology: GNAT (Gcn5-
related N-acetyltransferase), MYST (MOZ, Ybf2/Sas3, Sas2, and Tip60) and 
CBP/p300; they have a limited substrate specificity, since they are able to add acetyl 
groups to many different lysine residues. The modified residues are mainly in the N-
tail of the histones, and the neutralization of the positive charges given by the 
acetylation destabilizes the interaction between the nucelosomal proteins and the 
DNA [207]. There are also additional sites for acetylation within the globular 
structure of histones, facing the DNA major groove, such as K56 on histone 3 
acetylated by Gcn5 in humans, which results in the disruption of the electrostatic 
interactions between DNA and histone cores, starting DNA unwrapping [209-210].  
Acetylation of both histones 3 and 4 has been identified as a mark for active 
chromatin and HATs activity has been characterized in this context. Gcn5 is a part of 
an activator complex called SAGA (Spt-Ada-Gcn5 acetyltransferase) and is able to 







(NuA4), preferentially acetylates H4 and H2A. Both complexes are recruited by 
specific activators to the promoters of genes that are transcriptionally active [211].  
The cooperation between HATs and chromatin remodeling complexes has been 
described in several cases, since acetylated histones are known to be binding sites 
for other proteins involved in gene regulation, such as the SWI/SNF remodeling 
complex, which is able to bind and acetylate histones and is involved in nucleosomal 
mobilization [212]. Tip60 has been identified together with Brg1 (a SWI/SNF 
chromatin remodeler family member) as a factor affecting the regulation of several 
developmental genes [213]. Moreover, the presence of other histone modifications 
such as H3K4 methylation (in the promoter) and H3K36 methylation (in the coding 
region) can also play a role in HAT recruitment, since proteins able to recognize 
methylated residues also take part in the formation of HAT-containing complexes 
[214]. 
The enzymes responsible for the reverse reaction, namely the removal of the acetyl 
groups, are named Histone Deacetylases (HDACs), and their action restores the 
positive charge of the lysine, therefore stabilizing the chromatin structure. HDACs 
are divided into four classes: class I, II and IV share some sequence homology and 
need Zinc as a cofactor; class I and II are homologous to yeast (sc)Rpd3 and 
scHda1, class IV is composed only by HDAC11, class III (also called Sirtuins) are 
homologous to scSir2 and are NAD+ dependent (extensively reviewed in [215-216]). 
HDACs not only act on chromatin, but are involved in the tuning of multiple 
intracellular signaling pathways, showing low substrate specificity. At the 
transcriptional level, HDACs are able to induce repression of transcription not only by 
restoring the net positive charge of the lysine residues, therefore reducing the 
affinity of histones for several transcription factors, but also increasing the affinity 
for transcriptional repressors, such as proteins containing the SANT domain, which 
recognizes unmodified histones [207, 214, 217]. 
To conclude, paradoxically, HATs are also found at inactive gene promoters, where 







active genes, since they are required to ensure proper transcription initiation and to 
commit genes to rapid repression [214, 219]. The pattern of histone tail acetylation 
can also regulate chromatin compaction dynamics, with a direct effect on chromatin 
structure, since there are evidences that acetylation in H4K16 inhibits the formation 
of the compact 30 nm fibers [220-221].  
Histone phosphorylation  
Histone phosphorylation is a highly dynamic process occurring on serine, threonine 
and tyrosine residues present in the N-tail of histones, able to modify the net charge 
of the chromatin thanks to the transfer of a negatively charged phosphate group on 
the side chain of the target amino acid. Several cellular kinases have been found to 
bind chromatin, suggesting their active role in chromatin phosphorylation [222]. 
Phosphorylated residues in the histone tails behave as docking sites for signaling 
effectors and adaptors, as 14-3-3 proteins, which have been characterized as 
downstream effectors [223]. Histone phosphorylation plays a role in different 
processes, including gene expression, DNA damage response and chromatin 
compaction (reviewed in [224]).  
Regarding the regulation of gene expression, H3S10, T11 and S28 phosphorylation 
is associated to Gcn5-dependent histone acetylation, strongly supporting the 
existence of a crosstalk between acetylation and phosphorylation to promote 
transcription activation [224]. In some cases, activation of the transcription can be 
achieved through an allosteric regulation of the protein complexes present on the 
chromatin. As an example, H3S28 phosphorylation can be correlated to transcription 
activation through the displacement of the Polycomb repressive protein complex, 
which acts on the upstream amino acid (H3K27) in the histone tail. Moreover, H3Y41 
phosphorylation activates transcription by disrupting chromatin binding by the 








Ubiquitination, most frequently monoubiquitination, is a covalent modification 
occurring on lysine residues of the histone proteins assembled as octamers in the 
nucleosomes, as well as in the linker histone H1. The best characterized is the role 
of H2AK119 and H2BK120 (K123 in yeast) ubiquitination [207]. H2A-ubiquitin ligases 
are often found in transcriptional repressor complexes, as it is the case for Ring1, a 
member of gene silencing-related Polycomb Group protein 1, discussed later in 
details [225], while H2B ubiquitination is associated to active gene expression, 
promoting transcriptional activation and elongation [226-227].  
Histone methylation  
Histone methylation consists in the transfer of a methyl group from S-
adenosylmethionine to the side chains of lysine or arginine residues; this 
modification does not affect the net charge of chromatin, but creates docking sites 
for different combinations of interacting proteins, able to modulate the downstream 
signaling. This chemical modification shows an additional level of complexity, since 
lysine residues can be mono-, di- and trimethylated, while arginines can be mono-, 
symmetrically or asymmetrically dimethylated [207]. This allows a wide combination 
of interactors to be recruited and be responsible for modulating the transcriptional 
cascade.  
Arginine methylation 
There are two classes of arginine methyltransferase (PRMTs): type-I PRMTs are 
responsible for monomethylation and asymmetric dimethylation, while type-II 
PRMTs are responsible for monomethylation and symmetric dimethylation [228]. 
PRMTs are recruited to promoters through specific transcription factors [229] and 
are able to methylate not only histones but transcription factors and coactivators as 
well, therefore impacting on a wide range of effector molecules. The role of arginine 







H3R2 methylation, transcription is inhibited, since the K4 methyltransferase complex 
Mll1 does not methylate H3K4, a known mark of active chromatin [230]. To date, 
few interacting proteins with methylarginine residues have been described. Recent 
evidence suggests that the de novo DNA methyltransferase Dnmt3A can recognize 
symmetrically methylated H4R3, therefore promoting DNA methylation and gene 
silencing [231]. A potential binding protein for asymmetrical arginine methylated 
histones has been recently identified in Tdrd3, which is able to recognize methyl 
marks associated with transcriptional activation (H3R17me2a and H4R3me2a), 
possibly being recruited on active gene promoters [232].  
 
Lysine methylation  
Many different enzymes responsible for lysine methylation have been identified, 
called histone lysine methyltransferases (HKMTs), divided into two families: the Set-
domain-containing protein family and the non-Set-domain-containing family Dot1 
[233]. Their target sites mainly reside in the N-tail of the histones, with the 
exception of H3K79 which is inside the globular structure [207]. HKMTs display a 
specific substrate specificity, being able to methylate only one specific residue; 
moreover, they can be so specific to catalyze only one state of the methylation (for 
example, Set7/9 is only able to monomethylate its target H3K4 [234]).  
Methylation has been considered for long time as a static modification, but since 
2002 many demethylases have been identified, for both lysine and arginine. The first 
identified lysine demethylase is Lsd1 (Lysine-specific demethlyase 1), which is only 
able to demethylate mono- and di-methylated substrates, having different functions 
according to its molecular partners. It can demethylate both H3K4 me1/2 and H3K9, 
so it can act both as a repressor, in complex with Co-REST, and as an activator of 
transcription [235-237]. In 2006, another class of enzymes, able to demethylate 
trimethylated lysines, was discovered [238-239]. The first identified member was 
Jumonji domain 2 (Jmjd2), able to demethylate H3K9me3 and H3K36me3. Its 







lysine demethylases except Lsd1. All these enzymes also display a high level of 
substrate specificity [240]. 
Lysine methylation has been linked to either active or inactive transcription. 
Methylation of H3K36, H3K79 and H3K4 are correlated to transcriptional activation, 
H3K4 and H3K36 methylation are also involved in transcriptional elongation.  
H3K36 methylation, which can be mono-, di- or trimethylation, has also a role in 
preventing transcription from inappropriate sites, since it has been reported that 
Eaf3 (subunit of Rpd3S histone deacetylase complex) binds di- and trimethylated 
H3K36 (H3K36me2 and me3), therefore moving the HDAC complex to the coding 
region [219, 241-242]. 
H3K79 methylation is catalyzed by Dot1 and can be present as H3K79me1, -me2 or 
-me3. Interestingly, H3K79 and H2BK123, a residue which can undergo 
ubiquitination, lie in the proximity of the same exposed nucleosome surface; an 
interplay of the two modifications has been demonstrated, since H2BK123Ub is a 
prerequisite for H3K79 and H3K4 methylation [243]. Its genome-wide localization 
analysis reveals an enrichment in gene coding regions, consistent with its deposition 
concomitant to the elongation by RNA Pol II. 
H3K4 is methylated mainly by Set1 in the ORF of active genes [220]; 
monomethylated residues are predominant at the 3’ of the ORF, dimethylation peaks 
in the middle and trimethylation surrounds transcription starting sites and the 5’ of 
the ORF, therefore positively correlating with gene expression [244]. The methyl 
mark at the 5’ of the ORF seems to be critical for transcription initiation and Pol II 
recruitment. H3K4 does not influence elongation or Pol II activity per se, but H3K4 
methylated histones are recognized by chromatin remodeling complexes as NURF 
[245] and this modification prevents the association of negatively acting nucleosome 
remodelers and histone deacetylation complexes (NuRD) [246]. Methylated H3K4 is 
also recognized by Isw1, a subunit of the Isw1 ATP-dependent chromatin 
remodeling complex [247] and by members of SAGA complex (an acetyltransferase 







of methylated H3K9 impairs the methylation of H3K4, possibly making electrostatic 
interaction with the HKMTs, therefore preventing its action on H3K4 [250]. 
Lysine methylation marks associated with transcriptional repressions are H3K9, 
K3K27 and H4K20 [233].  
H3K9 is linked to heterochromatin subdomains and gene silencing. Transcriptionally 
inert regions at pericentric chromatin are marked by H3K9 methylation, which is 
recognized by Heterochromatin Protein 1 (Hp1) [251-252]. It is also linked to X 
chromosome inactivation [253-254]. An interesting link between H3K9 methylation 
and DNA methylation has been proven in a variety of organisms: in Neurospora 
Crassa, HKMT Dim-5, which methylates H3K9, is necessary to direct DNA 
methylation [255-256]. In mammals, at peri-centromeric chromatin, DNA 
methylating enzymes are recruited to H3K9-methylated heterochromatin through 
direct interaction with Hp1 [257]. H3K9 methylation is not restricted to constitutive 
heterochromatin, since HKMT are active also in repressing euchromatin targets, 
through the recruitment of HP1 at the promoter of repressed genes [258]. H3K9 
methylation can be present as mono-, di- or trimethylation (H3K9me1, me2 or me3 
respectively). The methylation distribution has been extensively studied, 
demonstrating that H3K9me1 is enriched in gene promoters and 5’ UTR regions, 
while it is minimal in intergenic regions; H3K9me2 is a mark of heterochromatin, 
prevails at peri-centromeric and subtelomeric regions, but also covers large genomic 
areas encompassing coding and non coding regions; H3K9me3 has previously been 
found in heterochromatin regions and on repressed promoters, but more recently 
has been shown to be present also at gene bodies of actively transcribed genes, 
together with ϒ-isoform of Hp1 [259-260]. 
H4K20 is the only methylation site on histone 4. Depending from the degree of 
methylation, H4K20 can exert different roles. K20me1 has been linked with 
transcriptional repression [261], cell cycle regulation [261-262], X chromosome 
inactivation [263] and nucleosomal compaction. H4K20me2 plays a role in the 







DNA double strand breaks response. H4K20me3 is highly enriched in pericentromeric 
heterochromatin, in combination with H3K9, probably acting as binding sites for 
proteins involved in heterochromatin formation; interestingly the HKMTs responsible 
for H4K20 methylation are not able to act on pericentromeric chromatin in the 
absence of HP1 and H3K9 methylation [264-265]. 
Polycomb Group (PcG) proteins 
H3K27 can be found in mono-, di- or trimethylation state, and the distribution of the 
different methylation levels is not homogenous: H3K27me1 is enriched at 
pericentromeric chromatin, at major and minor satellite repetitive elements as 
H3K9me2 and H4K20me1 and in X-inactivated chromosomes; H3K27me2 and 
H3K27me3 are spread in silent regions of euchromatin; moreover, H3K27me3 is 
absent in repetitive elements while it regulates directly many key genes in 
development and differentiation. H3K27 methylation was discovered as a regulator 
of the homeotic genes in Drosophila, where repression of the developmentally 
regulated Hox genes by the proteins of the Polycomb Group (PcG) was discovered 
as antagonists of Tritorax-mediated transcriptional activation [266]. It became later 
clear that a wide variety of genes are associated to this modification. The core 
complex responsible for H3K27 methylation is Polycomb Group of proteins, well 
conserved from Drosophila to mammals [267-271]. PcG proteins are mainly 
assembled into two multicomponent complexes, called Polycomb Repressive 
Complex 1 (PRC1) and Polycomb Repressive Complex 2 (PRC2). PRC2 is composed 
of Suz12, Eed, RbAp46/48 and Ezh1/2, which is the enzyme responsible for 
methylation of H3K27 (Fig.10, left). Ezh2 is essential to di- and tri-methylate 
H3K27, while it is dispensable for monomethylation, possibly carried out by a 
complex involving Ezh1 [272-274]. Some additional proteins are associated with 
PRC2: Aebp2 enhances the enzymatic activity of the complex, PCL is able to interact 
with PRC2 through Ezh2, and Jarid2, a member of the Jumonji family of lysine 







of catalytic activity. This protein interacts with Ezh2, and probably has an inhibitory 
effect on lysine methylation mediated by PRC2; it recognizes similar sequences to 
the PRC2 target sequences, therefore it can have a role in the recruitment of PRC2, 
as well. PRC1 in mammals is composed by the Cbx (Chromobox-domain) protein, 
which recognizes H3K27me3 through a chromodomain, by one member of PCGF 
family, of the Ring family (Ring1a and -1b) and of the Hph family. Ring proteins are 
responsible for the ubiquitination of lysine 119 of H2A (Fig.10, right). 
 
Figure 10. Components of PCR2 and -1.  
 
The common model of recruitment of PcG complex implies that its target genes are 
recognized by PRC2, which methylates H3K27. This mark acts as a binding site for 
PRC1 through Cbx; the PRC1 member Ring has a ubiquitin E3 ligase activity specific 
for lysine 119 of histone 2A. This triggers an inhibition of the transcription either by 
recruiting silencing proteins or by interfering with initiation or elongation steps [225, 
275-276].  
Interestingly, even if the Polycomb mediated silencing mechanism is well conserved 
through evolution, the mechanism of recruitment of PRC to its target is not. In 
Drosophila, PcG protein complexes are recruited by DNA motifs called Polycomb 
response elements (PRE), recognized by a variety of transcription factors, mainly not 







perfect correlation with the CG-rich elements [277]. Several mechanisms have been 
proposed to explain PRC2-targeting to these regions: the core components of PRC2 
complex could act synergistically to target it to CG-rich regions, since they show 
moderate affinity of CG-rich stretches; sequence specific transcription factors could 
regulate PRC2 binding to the targets; long non coding RNAs could play a role in PcG 
proteins recruitment, since it has been reported that the long non coding RNA Xist 
can interact with PRC2 [176]. Recent evidence has however reported the 
identification in mammals of sequences recognized by PcG showing similarity with 
the Dorspohila PRE, suggesting an important role for Yy1, the mammalian 
orthologue of Drosophila PRE DNA-binding protein Pho [278-279]. It was recently 
shown that non-canonical PRC1 complexes are not only dependent on H3K27 
methylation for their recruitment, but can also interact with sequence specific DNA-
binding proteins, which could target the complex to a specific site on the genome 
[280]. 
H3K27 methylation has been implicated in various biological processes, such as X 
chromosome inactivation, genomic imprinting and silencing of developmentally 
regulated genes [233]. More in detail, genome-wide mapping of PcG complexes 
shows that they are bound to the majority of the genes involved in key 
developmental pathways and reside at the promoters of a very large number of 
tissue-specific differentiation genes [281] playing a key context-dependent role in 
the maintenance of stem cell proliferation and in many differentiation processes 
[282-283]. Interestingly, H3K27 trimethylation correlates with PRC2 promoter 
occupancy and covers up to 20% of embryonic stem cell promoters. These 
promoters, however, are also marked by H3K4me3, correlating with active 
transcription [284-285]. These are the so-called chromatin “bivalent domains”, well 
described in embryonic stem cells. They cover genome regions where genes are 
“primed” to be quickly activated upon arrival of differentiation signals, but in the 







decision, bivalent “genes” lose the active marks and repress transcription through 
H3K27me3. 
The PRC2 complex can contain alternatively the Ezh1 or Ezh2 methylating enzyme. 
PRC2-Ezh1 and PRC2-Ezh2 occupy an overlapping set of genes, probably co-
occupying them, but their expression profile is very different; Ezh1 is ubiquitously 
expressed, while Ezh2 is strongly associated with proliferative tissues. Ezh1, which is 
able to efficiently methylate H3K27 in vitro, shows very low levels of methyl-
transferase activity in vivo. Indeed, Ezh2 knockdown strongly affect global 
H3K27me2/me3 levels. PRC2-Ezh1 acts by strongly repressing transcription through 
the induction of chromatin compaction. It has been proposed that the PRC2-Ezh2 
complex establishes the de novo methylation pattern, being later downregulated, 
with PCR2-Ezh1 and PRC1 keeping the chromatin repressed [201, 273]. 
A recent report hypothesized a completely new function for Ezh1. The authors 
characterized Ezh1 occupancy genome-wide in myoblasts and in myotubes, and 
noticed that the majority of Ezh1 sites overlapped with H3K4me3 and RNA Pol II 
sites, suggesting that genes bound by Ezh1 are actively transcribed [286]. This 
observation reveals a potential role for PcG complexes in promoting mRNA 
transcription, in contrast to the well-documented role of PcG as transcriptional 
repressors. 
 
ATP-dependent chromatin remodeling complexes  
The ATP-dependent chromatin remodeling complexes use energy derived from ATP 
hydrolysis to move, destabilize, eject or restructure the nucleosomes. The need for 
chromatin remodelers is due to the necessity to have a regulated DNA accessibility 
in many different contexts, such as after replication, when the nucleosomes have to 
be placed at the proper distance; during DNA repair, when nucleosomes have to be 
ejected or shifted to provide access to chromatin; in the exposition of normally 
unexposed sequences which have to be bound by a variety of factors; during the 







impede their progress and they have to be displaced and later repositioned in the 
proper place. 
The chromatin remodelers share a conserved ATPase subunit homologous to the 
ATPase domain of ATP-binding helicases of the DEAD/-H family, comprised of two 
parts separated by a linker [287]. According to the additional presence of a unique 
domain adjacent to the ATPase domain, involved in recognition of modified histones, 
modulation of ATPase activity and interaction with chromatin, chromatin modifying 
enzymes and transcription factors [287-288] they are then classified into 4 different 
families called ISWI (imitation switch), CHD (chromodomain, helicase, DNA binding), 
INO80 (inositol requiring 80) and SWI/SNF (switching defective/sucrose 
nonfermenting) (Fig.11).  
 
Figure 11. Chromatin remodeler families, defined by their unique domains 
adjacent to the ATPase  domain. 
 
ISWI remodelers are composed of 2 or 4 units. Beside the conserved ATPase 
domain, ISWI complexes share the presence of a SANT domain adjacent to a SLIDE 
domain at the C-terminus, acting together to recognize the nucleosome unit, 
identifying both DNA and histones. ISWI complexes have been firstly described as 







exhibit developmental defects related to reduced expression of homeotic genes and 
NURF has been demonstrated to directly interact with transcription factors [289]. 
Beside this role of positive regulation of gene expression when ISWI is present in 
euchromatin regions, they have also been shown enriched in heterochromatin 
regions, playing a role in heterochromatin formation: mutant ISWI results in 
decondensed chromosomes in flies, reflecting a role in chromatin compaction [290]. 
This phenotype is consistent with the role of ISWI to catalyze the deposition of 
properly spaced nucleosomes. Interestingly, an inhibitory role on genes transcribed 
by RNA Pol I and III has been demonstrated, and the repression is related to ISWI-
mediated recruitment of HDAC1 and DNA methyltransferases [291]. The distinct 
subunits which can form ISWI complexes possibly explain the opposite role of the 
processes in which ISWI family is involved [292].   
The CHD family is characterized by N-terminal tandem chromodomains in addition to 
the conserved DEAD/H-related ATPase domain. CHD members are then subdivided 
into groups, according to similarities in domain structure. Chd1/2 have an additional 
C-terminal DNA domain; they can act as monomers or dimers, and they interact with 
HAT related complexes as SAGA and SILK [293-294]. They are targeted to sites of 
active transcription and associate with pre-initiation factors to favor transcriptional 
elongation [295]. Consistently, genome-wide binding of Chd1 correlates with 
H3K4me3 and RNA Pol II in ES cells, where probably is required for the maintenance 
of an open chromatin state [296]. Chd3/4 lack the DNA binding motif but they share 
N-terminal paired PHD finger domains; they are incorporated in a large protein 
complex with histone deacetylases called NuRD. The role of CHD is to facilitate the 
access to acetylated histones on the chromatin for the action of HDACs [297]. Chd5 
is predominantly expressed in neural tissues and in testis and has been 
characterized as a tumor suppressor associated with neuroblastoma. It probably 
works by forming a nucleosome remodeling and deacetylation (NuRD) complex that 
regulates transcription of specific genes [298]. Chd7 seems to be involved in the 







to interact with Brg1 (a SWI/SNF family member) to regulate the neural crest 
transcriptional program [299-300]. 
INO80 remodelers were firstly isolated in yeast, in which ino80 mutants are 
defective for the transcriptional activation in response to inositol depletion [301]. 
INO80 complexes are composed of 10 subunits [301]. The common core is the split 
ATPase domain with a long insertion present in the middle of the ATPase domain, 
which acts as a scaffold for the association of two proteins called Rvb1 and Rvb2, 
which form a hexameric structure and exhibit helicase activity, binding replication 
forks [292, 302]. INO80 members also share a N-terminal helicase-SANT-associated 
(HSA), which acts as a docking site for various interactors. INO80 complexes can 
slide nucleosome and evict histones from DNA. Srw1 (in yeast, Srcap in human), a 
member of INO80 family, has the unique ability to restructure the nucleosome by 
removing canonical H2A-H2B dimers and replacing them with H2A.Z-H2B dimers. 
They exhibit several functions, as INO80 members can act at the promoter level 
regulating gene expression both positively and negatively.  
The SWI/SNF family has been originally isolated in yeast, where the complex is 
composed of 8 to 14 subunits. The SWI/SNF complex contains the ATPase 
Swi2/Sbf2p and other subunits involved in DNA and protein-protein interactions. It is 
able to alter nucleosome structure in an ATP-dependent manner. The catalytic 
ATPase included an HSA (helicase-SANT) domain and a C-terminal bromodomain. 
There is also a closely related complex named RSC (Remodeling the structure of 
chromatin), which has an ATPase related to Swi2/Snf2p and the protein complex is 
formed by analogs of the members of SWI/SNF. Interestingly, the RSC and SWI/SNF 
are found at different chromatin regions, displaying non redundant function [292]. 
In mammals, there are two homologues complexes to SWI/SNF and RSC called BAF 
(Brahma-associated factor) and PBAF. The BAF complex has been shown to be 
fundamental for correct heart development. The complex can include alternatively 
Brg-1 or Brahma ATPase and is important in the regulation of a variety of 







[303], it is also involved in myocardial proliferation in the embryo and in the control 
of gene expression of embryonic specific genes concomitant with the repression of 
adult specific genes [304]. Its deletion in secondary heart field precursors results in 
a hypoplastic right ventricle and in impaired outflow tract [304]; moreover, BAF 
member Baf60c is essential for the correct looping of the heart [305-306]. 
 
DNA methylation 
DNA methylation represents another epigenetic modification able to profoundly 
affect gene expression. In vertebrates, it occurs on position 5 of the cytosine within 
the dinucletide CpG, leading to the formation of 5-methylcytidine (5mC) (Fig.12).  
 
Figure 12. DNMTs catalyze the covalent addition of a methyl group to position 5 
of cytosine [307]. 
 
Historically, DNA methylation was considered as a defense system of the host 
genome against retrotransposons. It has also been connected to heterochromatin 
formation, transcriptional silencing, control of gene expression during development, 
imprinted gene expression, X chromosome inactivation and silencing of repetitive 
elements [308]. 
The discovery of methylation on cytosine residues dates back to 1975, when it was 
hypothesized that the methylation pattern of DNA can be inherited through somatic 
cell divisions and that it is related to gene silencing [309]. DNA methylation occurs 
through the action of a family of enzymes called DNA methyltransferases (DNMTs), 
which are required and essential for embryonic and neonatal development [310-







substrates: Dnmt1 is the maintenance methylase, which recognizes the methylated 
CpG residues of the hemimethylated DNA generated during DNA replication and 
methylates the opposite strand, while Dnmt3a and -3b are responsible for de novo 
methylation, introducing methyl groups on previously unmethylated CpG sites [311-
312] (Fig. 13).  
 
Figure 13. Schematic representation of mechanisms involved in DNA methylation 
and demethylation [307]. 
 
De novo methylation occurs in germ cells and early embryos as a response to the 
massive wave of demethylation previously occurred. After fertilization, the paternal 
genome is actively demethylated, while the maternal genome seems to be passively 
demethylated; after implantation, de novo methylation reestablishes the DNA 
methylation pattern which will be maintained, in large part, in all the somatic tissues 
[313-314]. Moreover, de novo methylation occurs during lineage-specific 
differentiation, such as in hematopoietic progenitors [308, 315]. The same process 
also regulates genomic imprinting and X-chromosome inactivation.  
An essential role in methylation establishment is also attributed to Dnmt3L, a protein 
that lacks intrinsic catalytic activity but shares sequence similarity with DNMTs. 







with two copies of Dnmt3L and that this tetramer is able to methylate two CpG sites 
preferentially separated by 8-10 bps. CpG periodicity is not enough to fully explain 
how de novo methylation is targeted to specific sequences [307, 316-317]. 
Targeting of DNMTs can be achieved via multiple pathways. In cancer cells, different 
factors, as the fusion protein Pml-Rar [318] or c-Myc [319] have been demonstrated 
to recruit DNMTs, stimulating the methylation of target gene promoters, therefore 
leading to the hypothesis that DNMTs targeting could be regulated by interaction 
with repression proteins.  
Another mechanism to target de novo methylation is the interaction between DNMTs 
and histone tails. The repressive mark H3K9me3 is recognized by Hp1, able to 
recruit Dnmt3A, which catalyzes the methylation of target promoters in embryonic 
stem cells [320] as well as DNA satellite repeats at pericentromeric heterochromatin 
[257]. The lack of modification at H3K4 (H3K4me0) is also strongly correlated with 
DNA methylation: H3K4 methylation prevents de novo methylation, since DNMT3-
associated protein Dnmt3L can specifically interact with unmethylated H3K4, and is 
blocked if H3K4 is methylated [321-323]. Notably, H3K4me3 can act as a binding 
site for H3K9me2 demethylases; since it seems that Hp1-mediated interaction with 
H3K9 recruits Dnmt3a/b, this could suggest that an interplay between different 
histone lysine methylation pattern could influence DNA methylation [324]. The 
relationship between Polycomb-mediated transcriptional repression and DNA 
methylation has not been completely elucidated yet. In many cases, DNA 
methylation and Polycomb silencing seem to be alternative mechanisms, since 
H3K27 methylation marks in embryonic stem cells coincide with CpG islands, which 
were thought to be devoid of DNA methylation. However, some evidences show that 
the two epigenetic modifications can act in cooperation, as in a model of 
differentiation from embryonic stem cells toward neurons, in which a subset of the 
genes which are marked by H3K27 trimethylation at the ES-cell state are four times 
more likely to acquire DNA methylation [325], and in cancer stem cells, in which the 







DNA level [326]. In vitro biochemical data also proved that Ezh2 can bind DNMTs 
[327], even if it seems that the interaction is not enough to trigger DNA methylation, 
probably due to the absence of additional regulatory factors of histone marks 
required for DNMT activity [328]. A recent report suggests that Dnmt3L can interact 
with PRC2, in competition with Dnmt3a and Dnmt3b, therefore maintaining a 
hypomethylated pattern at H3K27me3 regions [329].  
DNA methylation covers up to 70-80% of the genome. Its pattern is not a 
continuum along the genome, but displays a bimodal distribution: genomic regions 
can be hypo- or hypermethylated. CpG methylation can occur in genes, intergenic 
regions, transposons [330]. The only regions usually devoid of methylation are the 
so-called CGI (CpG islands), discussed later. 
The mechanisms regulating the relationship between silencing and DNA methylation 
are still not completely clarified. A first hypothesis postulated that the presence of 
DNA methylation on the cognate DNA sequences can directly inhibit the binding of 
transcriptional activators [331] (Fig.14A). Another hypothesis is that methyl-
binding-proteins (MBP) recognize methylated DNA and recruit corepressors to 
silence gene expression (Fig.14B). A third option is that DNMTs, in addition to their 
enzymatic role in the establishment of the 5mC pattern, couple methylation with the 
recruitment of enzymes able to modify chromatin, since it has been proven that they 
can interact with histone deacetylases and chromatin remodeling factors [312, 332] 
(Fig.14C).  
 










Beside the well established role in silencing, it is now evident that CpG methylation 
in gene bodies is related to transcription. It has been also proposed that H3K36m3, 
which associates with transcriptional elongation but not initiation, might be involved 
in recruitment of DNMTs [333]. Recent work involving whole genome sequencing 
identified an enrichment of DNA methylation in exons compared to introns, possibly 
suggesting a role for methylation also in splicing regulation [334].  
The best characterized role of DNA methylation involves the methylation occurring at 
the promoter level. In the mammalian genome, between 55% and 70% of gene 
promoters are associated with CpG islands (CGIs), which are sequences of DNA with 
CG content over 55%, approximately 1000 bps long and the often encompassing the 
transcription start site [330]. CGI promoters are usually unmethylated and 
transcriptionally permissive. They were originally considered to be a feature of 
housekeeping genes, therefore never methylated, but it is now evident that tissue-
specific genes also have CGI promoters. CGI promoter methylation can occur in 
differentiation processes [325] and during the establishment of X chromosome 
inactivation [335], as it correlates with long-term stabilization of transcriptional 
silencing. It seems to be a mechanism to lock the gene in a repressed state, not the 
initiation event for silencing. 
The reason why CGIs promoters are usually devoid of DNA methylation is not clear. 
Many mechanisms have been proposed: it seems unlikely that CGIs could be 
refractory to de novo methylation by DNMTs due to their DNA sequence; CGIs could 
be targeted by DNA demethylation mechanisms, but such demethylating activity in 
somatic tissues has not been identified yet; the presence in the CGIs of transcription 
factors or of specific histone modifications, as H3K4me3, could prevent DNMTs 
binding [336]. Additionally, it has been proposed that, since CGIs correlated with 
actively transcribed genes and since TSS of active genes are nucleosome-depleted, 
DNMTs are lacking the substrate for the de novo methylation, as their preferential 







About 50% of CGIs are located in TSS proximity, while the other CGIs are the so-
called “orphan CGIs”. In these CGIs, which display high variability in the methylation 
pattern in different somatic cells and tissues, the chance of acquiring methylation is 
significantly higher than in the CGIs present at promoters, especially in the 
intragenic CGIs [338]. The role of this methylation is still under debate: it could be 
linked to the aforementioned role of DNA methylation in gene bodies, or it could 
regulate alternative splicing. Interestingly, some non-coding RNAs have CGIs in their 
promoters, which remain unmethylated, therefore putting forward the possibility 
that some of the so-called “orphan CGIs” could correspond to regulatory RNAs 
promoters.  
As mentioned above, less then 70% of annotated gene promoters are associated 
with CGIs, but the remaining fraction of genes does not show CpG islands in the 
promoter region. DNA methylation in this context has not been completely clarified 
yet; substantial fluctuations of the DNA methylation pattern occur in these genes, 
where methylation seems to be more tissue-specific and dynamic compared to CGI 
promoter methylation [337]. 
The reverse process, DNA demethylation, is still poorly understood in mammals. 
DNA methylation can be achieved either passively, not methylating newly 
synthesized DNA after replication therefore “diluting” the methylated cytosines, or 
actively, in a replication-independent process. Passive demethylation is probably 
occurring during mammalian development in the maternal genome during pre-
implantation growth [339], and it requires active cell division. In other tissues, both 
during embryonic development and in adult somatic cells there are evidences of 
replication-independent, active demethylation [307]. The mechanism leading to 
demethylation of 5mC is still under debate, but it is likely that different enzymatic 
pathways can be responsible for it. In plants, demethylation is achieved by a family 
of four DNA glycosylases, which first remove the base and then cleave the abasic 
site leaving a nick, which is repaired through Base Excision Repair (BER) 







identified in mammals yet, and the known mammalian glycosilases show very weak 
activity toward 5mC demethylation [341]. Deamination of 5mC to tymine resulting in 
T-G mismatch is also a candidate mechanism to mediate demethylation, since the 
mismatch could be recognized and resolved by BRE, restoring unmethylated cytosine 
[342]. Recently, the discovery of 5-hydroxymethylcytosine (5hmC) in mammalian 
genomes has suggested new possible mechanisms for DNA demethylation. The TET 
family of proteins are the enzymes involved in the oxidation of 5mC to 5hmC [343]; 
moreover, they are capable of iterative oxidation leading to the formation of 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC); these base modifications are 
detectable in the DNA of ES cells, but are at least one order of magnitude less 
represented compared to 5hmC. 5fC and 5caC could be recognized by different 
interactors compared to 5hmC; moreover, due to their chemical structure, they 
destabilize the N-glycosidic bond. Different mechanisms have been proposed to 
explain 5hmC as an intermediate of DNA demethylation. 5hmC could be passively 
diluted contributing to demethylation, or the oxidized methyl group could be actively 
removed in order to restore cytosine, or the modified nucleotide could be excised 
and repaired through DNA repair mechanisms [344]. It has been recently discovered 
that thymine DNA glycosidases (TDG), while they have no excision activity on 5mC 
or 5hmC, have robust in vitro base excision activity on 5fC and 5caC properly paired 
to G in duplex DNA, suggesting that they could mediate base excision of oxidized 
nucleotides [345]. In line with the hypothesized role of TDG in DNA demethylation, 
these proteins are necessary for correct embryonic development: TDG-null embryos 
show decreased expression of developmental regulators, with perturbed DNA 
methylation in regulatory sequences [346-347]. 
 
EPIGENETIC REGULATION OF TRANSCRIPTION BY NOTCH 
 
The Notch signaling cascade appears to be quite simple, with no second messengers 







The transcription factor RBP-Jk plays a central role in transducing the Notch receptor 
cleavage signal to changes in gene expression, acting as either a transcriptional 
repressor or activator (Fig.15). When NICD migrates to the nucleus, it displaces the 
repressor complex associated to RBP-Jk through SKIP (Ski-interacting protein), 
which is stably associated to RBP-Jk in both the context of transcriptional activation 
and repression. SKIP is able to bind both the SMRT (silencing mediator of retinoid 
and thyroid hormone Receptors) corepressor complex and NICD, but this binding is 
mutually exclusive [348]. When NICD interacts with RBP-Jk, it acts as a bridging 
factor to form a ternary activator complex composed by RBP-Jk, NICD and 
Mastermind, a co-activator protein which is an integral part of the Notch signaling 
pathway [349-350]. Mastermind in turn recruits p300 [122, 351-353] or other 
known HATs, such as Pcaf or Gcn5, with cellular and tissue specificity [353-355] 
resulting in the formation of a multisubunit protein complex. Its combinatorial 
activity modulates the transcription at Notch-responsive promoters. The 
acetyltransferase complexes SAGA and Tip60 have been shown to be required for 
Notch and Mastermind activity for the correct wing development in Drosophila, 
probably enhancing the assembly of the Notch activator complex [356]. When the 
NICD signaling cascade is not activated, RBP-Jk interacts with distinct complexes of 
co-repressors: SKIP associates RBP-Jk and recruits SMRT/HDAC1 complex [357], 
therefore triggering transcriptional repression of Notch target genes. SHARP (SMRT 
and HDAC associated repressor proteins) interacts with RBP-Jk [358], acting as a 
“co-repressor hub” to recruit different complexes and contributing to the versatility 
of Notch regulated gene expression. The SHARP/RBP-JK complex have been shown 
to recruit Eto, a conserved nuclear protein not directly able to bind DNA, but 
exerting a negative regulation on transcription, interacting with corepressors as N-
CoR and SMRT [359] and recruiting HDAC1, -2 and -3 [360]. CtBP and CtIP, owing 
to the CoREST/Lsd1 complex, which recruits on the chromatin HDAC1/2 [361], are 
also known to interact with RBP-Jk/SHARP [149, 362]. Of interest, CtBP is necessary 








Figure 15. RBP-Jk mediates activation or repression of Notch signaling and 
interacts with different protein complexes in two opposite processes (adapted 
from [112]). 
A variety of histone modifications have been associated to Notch promoters, as 
markers of active or inactive transcription (Fig.16).  
H4K16 acetylation has been reported to play a dominant role on chromatin 
compaction and transcription, possibly disrupting a specific contact point between 
H4 and H2B. The enzyme responsible for this modification on Notch target genes 
promoters has not been identified yet, but Sirt1 has been reported to deacetylate 
H4K16, thus contributing to the silencing of Notch target genes [363]. In different 
models in Drosophila, H3K4 trimethylation has been reported to occur at Notch 
target gene promoters. These findings strongly support the possibility that histone 
methyltransferases are associated to the Notch-specific transcriptional complex 
when NICD is present, while demethylases are recruited in its absence [364-365]. 
The histone demethylase Lsd1, possibly recruited via SHARP-associated CtBP-Sirt 
complex [363], can associate with RBP-Jk [366] and can remove mono- and 
dimethylation on H3K4 [235]. Other demethylases, like Kdm5A have been reported 
to interact with RBP-Jk [367] and cooperate in the modulation of the chromatin 
environment at Notch target genes, as it happens in Drosophila [368]. The kinetics 







waves of demethylation take place, first involving Kdm5A/Lid (no longer needed 
after the removal of H3K4me3) and then Lsd1 [116]. Moreover, H3K4 trimethylation 
is also positively affected by the presence of H2B ubiquitination at Notch target gene 
promoters, therefore a functional crosstalk contributes to the complexity of the 
cellular responses to Notch activation [369]. 
The repressive mark H3K27 trimethylation the has also been described at Notch 
target gene promoters. A number of studies have established that PcG complexes 
are critical for both the proper function of Notch pathway and the expression of 
several Notch target genes [364, 370-371]. Studies in ES cells support the idea that, 
in order to activate Notch target genes transcription, H3K27me3 repressive marks 
are actively removed [372]. Moreover, a role for the PRC2 member Jarid2 has 
recently been postulated in the regulation of the Notch signaling during heart 
development. Jarid2 has been shown to repress Notch signaling pathway in 
embryonic heart development during the trabeculation process, possibly acting 
through histone lysine methylation [373].  
 








Chromatin remodeling factors are also involved in the control of Notch target gene 
expression. In vitro, it has been shown that a direct binding of SWI/SNF member 
Brahma to RBP-Jk occurs, both in the presence and absence of the NICD [374]. 
These results were supported by a genetic screen in Drosophila leading to the 
hypothesis that, once in the nucleus, NICD interacts with the Brahma complex, 
directly regulating its activity or bringing it to its target genes [375]. Moreover, in 
retinal stem cells/progenitors regulation, Brahma regulates progenitor commitment 
through attenuation of Notch signaling [376].  
Another protein acting as a bridging factor between RBP-Jk and the BAF chromatin 
remodeling complex is Baf60c. This is a subunit of the SWI/SNF-like BAF complex, 
which plays a pivotal role during heart development in Zebrafish and in mouse in the 
regulation of Notch-mediated left-right asymmetry. Its role on Notch target genes 
promoters is to stabilize the interaction between activated Notch and RBP-Jk. [305].  
Notch target gene silencing is also achieved through DNA methylation. In a model of 
dystrophic muscle, Notch1 is epigenetically silenced in response to elevated levels of 
TNF and NF-kB, triggering the block of the regenerative potential of satellite cells 
[377]. In human B cell acute lymphoblastic leukemia (B-ALL), hypermethylation at 
the promoters of both Notch3 and Hes5 was associated with decreased H3K4 
trimethylation and increase H3K27 trimethylation [378], therefore suggesting the 
formation of a transcriptional repressive chromatin environment at Notch target 
promoters. 
 
ADENO-ASSOCIATED VIRAL VECTORS 
 
Adeno-associated viruses 
Adeno-associated viruses (AAV) were first described in 1965 by Atchinson as small 
contaminants of Adenovirus preparations, unable to generate a productive infection 
in the absence of helper viruses as Adenovirus or Herpesvirus [379]. They are 







80% of the human population bears antibodies against AAV proteins, but, to date, 
no disease has been correlated to their infection.  
AAVs are small icosahedral non-enveloped virions with a diameter of 25 nm. Their 
genome is a single-stranded DNA molecule of approximately 4.7 kb, with 145 
nucleotide-long inverted terminal repeats (ITR) which form T-shaped hairpin 
structures at both ends of the genome, which are used as origins of replication and 
as primers for the second-strand DNA synthesis performed by the host DNA 
polymerase [380]. The double-stranded DNA intermediates are processed via a 
strand displacement mechanism, resulting in single-stranded DNA used for 
packaging and double-stranded DNA used for transcription [381]. Critical to the 
replication process are the Rep binding elements (RBEs) and a terminal resolution 
site (TRS) located within the ITRs. In addition to their role in AAV replication, the 
ITRs are also essential for AAV genome packaging, transcription, negative regulation 
under non-permissive conditions and site-specific integration (reviewed in [381-
382]) (Fig.17). 
 
Figure 17. Secondary structure of the AAV2 ITR (adapted from [381]). 
 
The AAV wild-type genome contains two ORFs encoding non-structural and 
structural proteins (Fig.18). The 5’ ORF encodes Rep gene, coding for four different 
nonstructural proteins transcribed using two different promoters within the same 
gene (p5 and p19) through differential splicing. Rep78 and Rep68 positively regulate 







specific DNA binding activity (binding at the RBE) and site- and strand-specific 
endonucleases activity (nicking at the TRS to process the double-stranded 
intermediates) [383]. Rep52 and Rep40 are involved in the generation and 
accumulation of single-stranded viral DNA to be packaged into AAV capsids. All the 
four Rep proteins show helicase- and ATPase-activity [381]. The 3’ ORF encodes the 
Cap gene, from which the three capsid proteins Vp1, Vp2, Vp3 are produced through 
different splicing sites and atypical translation start codons [384-385]. They differ 
from each other in the N-terminus and are assembled in a near spherical protein 
shell of 60 subunits with a ratio 1:1:10.  
 
Figure 18. Adeno-associated virus genome organization. 
 
AAV infection and viral life cycle 
According to their serotype specificity, the virions recognize different receptors on 
the cell surface. The originally discovered and best characterized serotype is AAV2, 
which binds heparan sulphate proteoglycans (HSPG) of the cell surface [386] and at 
least six coreceptors, including Vβ5 integrins, fibroblast growth factor receptor 1, 
hepatocyte growth factor receptor, Vβ1 integrin and laminin receptor [387]. AAV3 
also binds HSPGs; 3, O-linked and N-linked sialic acid are the known receptors for 
AAV4 and 5; the 37/67-kDa laminin receptor binds AAV8, AAV3 and AAV9 [388]; 
galactose is the primary receptor for AAV9 [389]; the epidermal growth factor 







After docking to the membrane receptors, AAV2, for which more information is 
available, is endocytosed in clathrin-coated vesicles through a dynamin-dependent 
pathway; viral endocytosis is stimulated by binding of the virus to the receptor, 
which activates intracellular signaling pathways that stimulate receptor 
internalization [391]. Following internalization, endosomal acidification is necessary 
to induce conformational changes in the AAV capsid which expose the Vp1 and Vp2 
N-termini outside the capsid, enabling the dissociation of the virus-receptor complex. 
The N-terminal of Vp1, buried inside the virion, contains a phopsholipase A2 domain 
necessary for the endosomal escape [392].  
The virions are released into the cytosol after endosomal acidification but before 
their maturation to lysosomes [393]. The proteasome also plays a role in AAV2 
trafficking, as its inhibition results in enhanced nuclear uptake of the virus [394].  
After the release into the cytoplasm, defined sequences at the N-terminal part of 
Vp1 and Vp2 act as nuclear localization signals and trigger AAV genome transport 
into the nucleus, where it is uncoated and undergoes conversion from single- to 
double-stranded DNA intermediates (circular and linear). The mechanisms driving 
this conversion is not completely clear. It was hypothesized that the ITRs are used 
as primers during the double strand synthesis, but more recent evidence proposes 
that double-stranded DNA could result from the annealing of the single stranded 
DNA to a complementary copy [395].  
In the presence of the Rep proteins, wild type AAV can also integrate its genome in 
the form of concatamers, preferentially in a region of human chromosome 19q13.3 
called AAVS1 [396-397]. The AAVS1 site and AAV genome do not who show 
extensive regions of homology, with the exception of a short sequence containing 
the the same tetranucleotide repeat (GCTC), which is bound by Rep proteins [398]. 
This sequence, therefore, is believed to mediate Rep78 and Rep68 binding to the 
ITRs and to a Rep-specific nicking site (TRS), thus facilitating site-specific 
recombination between viral and cellular sequences. The phenomenon of site-







considered attractive for a targeted stable transgene expression [399]. The minimal 
motifs necessary for AAV integration present in the AAVS1 locus, TRS and RBE, are 
located in the 5’UTR of the gene Mbs85 (myosin binding subunit 85), also called 
Ppp1r12c (protein phosphatase 1 regulatory protein) [400].  
When a cell bearing an integrated AAV genome is infected by the helper virus, a 
process of Rep-mediated excision of the viral genome from the host chromosome 
takes place, followed by a switch to the AAV lytic cycle. This event can only happen 
in the case of co-infection by Adenoviruses or Herpes simplex viruses, since the 
infection stimulates the cell to activate a set of genes with helper functions, allowing 
a permissive intracellular environment for AAV productive infection [381, 401] 
(schematic representation of AAV infection cycle in Fig.19). 
 
Figure 19. Cell entry and trafficking of Adeno-associated virus (adapted from 
[387]). 
 
Adeno-associated viral vectors 
Since 1984, AAVs have been considered as important tools for gene therapy, mainly 
because of their defective replication and their non-pathogenicity [402-403]. In the 
recombinant AAV (rAAV) genome, the Rep and Cap genes are replaced with the 
gene-expression cassette of interest, while the ITRs are maintained, since they are 







infected cells. Initially, the rAAV particles were produced by transfecting packaging 
cells (HEK293 or Hela cells) with the rAAV genome and a construct carrying the viral 
Rep and Cap genes, followed by the infection of the cells with a helper Adenovirus 
(Ad) for an effective AAV infection. In this system, the rAAV underwent a normal 
lytic cycle, being rescued from the plasmid backbone and then packaged into 
particles [382]. Even if the contaminating Ad were eliminated by extensive 
purification and heat inactivation, the Ad contamination was a persistent problem 
[404]. To avoid it, in the late 1990s the infection with the Ad was substituted by the 
transfection with a plasmid construct containing a mini-Ad genome, capable of 
propagating rAAV in the presence of AAV Rep and Cap, but incapable of producing 
infectious Ad [405]. To improve the efficacy of the production, nowadays the 
packaging cells are transfected with two plasmid constructs, encoding for the 
therapeutic gene cassette flanked by ITRs and for Rep and Cap proteins and 
adenoviral proteins providing helper functions [406]. This system greatly increases 
efficacy, resulting in 10-fold higher titers of rAAV preparations compared to the 
previous method [404]. Twenty-four hours after the transfection, the cells are lysed 
and the rAAV vectors are purified by cesium chloride, iodixanol gradient 








Figure 20. Recombinant AAV production system (adapted from [407]). 
 
The standard constructs contain the ITRs and Rep and Cap genes of AAV2. To 
produce rAAVs with different tropism it is sufficient to use during the generation of 
the rAAVs a chimeric construct containing the Rep gene of AAV2 and the Cap gene 
of the serotype of interest [408]. 
In order to efficiently transduce different tissues in vivo, a variety of different 
serotypes are used, some of which naturally isolated and others produced artificially. 
Tissue specificity is due to the different surface receptors recognized by these 
vectors. AAV1 and -6 are efficient in the transduction of the skeletal muscle; AAV5, -
7 and -8 efficiently transduce photoreceptors of the retina, while AAV5 and -4 
transduce the pigment epithelium; AAV6 and -9 transduce the entire airway 
epithelium, while AAV5 transduction is limited to lung alveolar cells. AAV8 transduces 
liver, endocrine and exocrine pancreas; AAV5 and -9 are used for central nervous 







For heart transduction, the first serotype used was AAV1, but additional studies 
demonstrated that capsid 9 confers the best cardiotropism in vivo in rodents [409-
411], triggering a stable gene expression up to at least one year both in pups and in 
adults [412-413]. Interestingly, 1x1011 vg/mouse are able to transduce up to 80% of 
host cardiomyocytes (compared to 14% of heart transduction with AAV8). Vectors 
display high transduction efficiency either if injected intravascularly (tail vein, portal 
vein) or extravasculary (subcutaneously or intra peritoneum) in neonatal mice, while 
in the adult intra peritonal injection triggers a localized efficient transduction of the 
peritoneum and the diaphragm [409].  
Recombinant AAVs are outstanding tools of the gene therapy of post-mitotic tissues, 
including the heart [409-410, 412, 414-415]. However, some caveats must be taken 
into consideration. In particular, AAV vectors are usually considered non 
immunogenic, based on animal studies, in which transduction of the liver was 
associated with the establishment of the immunological tolerance toward AAV vector 
and its transgene product [416-418]. However, results from a human clinical trial in 
which an AAV vector was injected into the liver for gene therapy of hemophilia B 
highlighted the possibility that transduction might lead to a cytotoxic T lymphocyte 
response towards the AAV capsid proteins, with consequent killing of the transduced 
hepatocytes [419-421]. Some strategies have been proposed to circumvent this 
problem, including the use of modified capsids [422], the transient 
immunosuppression of patients at the time of injection [423], the reduction of the 
dose of vector administered [419], or the introduction of vector into 










THE DECREASE OF CARDIOMYOCYTE PROLIFERATION 
AFTER BIRTH IS PARALLELED BY A REDUCTION IN NOTCH 
SIGNALING  
 
In order to characterize the role of Notch pathway in the regulation of 
cardiomyocyte proliferation, we set up an in vitro culture model for rodent neonatal 
and adult cardiomyocytes. Neonatal cardiomyocytes were extracted from newborn 
rats (1-2 days old) and kept in culture up to one week, in order to reproduce in vitro 
their physiological exit from the cell cycle in the post-natal heart. Adult ventricular 
cardiomyocytes were extracted from 2-months-old adult female Wistar rats with 
Langendorff perfusion system and kept in culture for 2 days, as a physiological 
model of cardiomyocyte maturation (Fig.21). 
 
Figure 21. Experimental settings for the in vitro cardiomyocyte culture. 







We first analyzed the proliferation rate of cardiomyocytes in our setting by the 5-
bromo-2'-deoxyuridine (BrdU) incorporation assay. BrdU was administered for 20 
hours before fixing the cells, which were subsequently processed for 
immunofluorescence analysis. We quantified the frequency of double positivity for 
the cardiomyocyte marker -actinin and for BrdU: while after 3 days of culture 
almost 10% of the cardiomyocytes can incorporate BrdU, indicating that they are 
still cycling, this fraction of cells is significantly decreased at day 7, when 
approximately 3% of the cells are still positive for BrdU and  become 0% in the adult 
cells, which were never detected BrdU+ (Fig.22A). We therefore stated, for our 
subsequent analyses, day 3 cardiomyocytes as proliferative cells and day 7 and adult 
cardiomyocytes as differentiated, non proliferating cells.  
We next performed mRNA expression analysis for Notch1 and its target genes. We 
focused our attention on the Notch1 gene, as Notch1 can autoregulate itself, and on 
the target genes previously shown to be regulated during cardiac development, 
Hes1, Hey1 and Hey2, and Cyclin D1. We detected that all Notch1 target genes 
showed significant decrease in their expression between proliferative (day 3) and 
non proliferative (day 7 and adult) cardiomyocytes, paralleling their exit from the cell 














Figure 22. Suppression of Notch pathway upon cardiomyocyte terminal 
differentiation.  
(A) Quantification of cardiomyocyte proliferation levels, assessed as the percentage of 
BrdU+, -actinin+ cells, of neonatal rat cardiomyocytes at days 3 and 7 after isolation and 
adult rat cardiomyocytes. Shown are the mean±sem of at least three independent 
experiments. **: P<0.01. 
(B) Transcription levels of Notch1 and its target genes in neonatal rat cardiomyocytes at 
days 3 and 7 after plating and in adult cardiomyocytes. Data are expressed to cellular HPRT 
mRNA levels. Shown are the mean±sem of at least three independent experiments. *: 
P<0.05; **: P<0.01. 
 
To understand the molecular changes accompanying the decrease of Notch 
signaling, we performed chromatin immunoprecipitation (ChIP) experiments on day 
3 (proliferative) and day 7 and adult (non proliferative) cardiomyocytes, in order to 
analyze the chromatin environment at Notch-responsive gene promoters. For each 
of the selected Notch1 target genes, sets of primers were designed and validated, 
mapping in correspondence of the gene transcription start sites (TSS). The 
housekeeping gene GAPDH promoter was used as a control (Fig.23A). We 
performed ChIP using antibodies detecting marks related to active chromatin 
(histone 3 pan-acetylation and  histone 3 lysine 4 trimethylation) and to Polycomb-
related repressive chromatin marks (histone 3 lysine 27 trimethylation, H3K27me3, 
hallmark of Polycomb Group protein 2 silencing and Ezh2 occupancy, being Ezh2 the 
only enzyme able to trimethylate lysine 27 on histone 3). When the cells were 
actively proliferating (day 3), Notch1 responsive genes were tagged by active 
chromatin marks, while in day 7 and adult non proliferative cells active chromatin 







(Fig.23B and C). The repressive chromatin marks showed an opposite behavior: 
H3K27me3 and Ezh2 occupancy were less present at day 3, when Notch1 signaling 
was active and cardiomyocytes were proliferating, while they were highly enriched in 
non proliferative day 7 and adult cells (Fig.23D and E). Collectively, these data 
indicate that, at Notch responsive promoters, chromatin moves from an active to an 
inactive state when the cells exit from the cell cycle.  
 
Figure 23. Chromatin modification at Notch target genes upon cardiomyocyte 
terminal differentiation.  








(B - E) ChIP analyses of Notch1 and target gene promoters on days 3 and 7 and adult 
cardiomyocytes using antibodies against active chromatin marks H3panAc, recognizing 
acetylated histone 3 (B) and H3K4me3, recognizing histone 3 lysine 4 trimethylation (C), and 
repressive chromatin marks H3K27me3, recognizing histone 3 lysine 27 trimehylation (D) 
and Ezh2 (E). Shown are the means±sem of at least three independent experiments. *:  
P<0.05; **: P<0.01 vs. day 3 
 
We also confirmed that the change in Ezh2 occupancy at Notch target gene 
promoters was not a consequence of Ezh2 upregulation over time: the analysis of 
Ezh2 expression level in neonatal cardiomyocytes at days 3 or 7 and in adult cells 
did not show an increase in its expression over time (Fig.24). 
 
Figure 24. Analysis of Ezh2 expression level along cardiomyocyte differentiation.  
Transcription level of Ezh2 in neonatal rat cardiomyocytes at days 3 and 7 after plating and 
in adult cells. Data are expressed to cellular HPRT mRNA levels. Shown are the mean±sem 


















STIMULATION OF NOTCH PATHWAY BY AAV-MEDIATED 
GENE TRANSFER INDUCES NEONATAL  CARDIOMYOCYTE 
PROLIFERATION IN VITRO 
 
Given the correlation between Notch1 signaling and the extent of cardiomyocyte 
proliferation, we wondered whether the exogenous activation of Notch pathway 
could lead to an extended proliferative window of neonatal cardiomyocytes, also 
considering the previous results from our lab [196] and the well documented role of 
Notch1 in driving proliferation in the last phase of fetal life [121]. We took 
advantage of the excellent properties of the Adeno-associated viral vectors (AAV) in 
efficiently and stably transducing myocardial cells both in vitro and in vivo. We first 
confirmed the high efficiency of AAVs as tools to transduce in vitro cultured 
cardiomyocytes. Transduction was performed contextually to plating with an AAV6 
vector encoding for EGFP at a m.o.i. of 1x104 viral genome (vg) per cell. GFP+, -
actinin+ cardiomyocytes were then quantified at days 3 and 7 of culture. 
Transduction efficiency was approximately 30% at day 3 and increased until 40% at 
day 7 (Fig.25A for representative images and 25B for quantification).   
 
Figure 25. Transduction of neonatal cardiomyocytes by AAV serotype 6 vectors.  
(A) Representative images of neonatal rat cardiomyocytes at days 3 and 7 of culture after 
transduction with AAV6-EGFP.  Scale bar 100 µm.  
(B) Quantification of neonatal cardiomyocyte positivity to GFP at days 3 and 7 after 








In order to exogenously stimulate the Notch pathway, we designed two AAV vectors 
encoding for different players of the Notch1 signaling cascade. One vector encoded 
the constitutively active Notch1 intracellular domain (AAV6-N1ICD), while the other 
vector coded for the soluble form of its ligand Jagged1 (AAV6-sJ1), which is secreted 
and can act as a soluble cytokine in the medium, activating Notch signaling in a 
contact-independent manner (Fig.26A). We transduced neonatal cardiomyocytes at 
a m.o.i. of 1x104 vg per cells contextually to plating, and we first analyzed transgene 
expression at days 3 and 7. Both the vectors were efficiently expressed and the 
transgene mRNAs were detectable at both days 3 and 7 (Fig.26B).  
 
Figure 26. AAV6-N1ICD and AAV6-sJ1 are efficiently expressed in neonatal 
cardiomyocytes.  
(A) Schematic representation of AAVs encoding for Notch1 intracellular domain (N1ICD) or a 
soluble form of Jagged1 (sJ1). ITR: AAV inverted terminal repeat. CMV: cytomegalovirus 
immediate early promoter. Poly A: polyadenylation site. 
(B) Expression level of AAV6 transgenes in days 3 and 7 rat neonatal cardiomyocytes. Data 
are expressed to cellular HPRT mRNA levels. Shown are the means±sem of at least three 
independent transduction experiments. 
 
While AAV6-sJ1-mediated signaling acts through the endogenous Notch1 pathway, 
AAV6-N1ICD should bypass the endocellular Notch1-processing steps. Therefore, in 
order to verify that the AAV6-N1ICD actually activates the canonical Notch signaling 
cascade in neonatal cardiomyocytes, we performed co-immunoprecipitation 
experiments to demonstrate that a physical interaction between the transgene 
molecule and RBP-Jk occurs. RBP-Jk was detected by Western blot in the protein 







specific antibody, demonstrating that the transgene acts through the canonical 
Notch1 pathway (Fig.27).  
 
 
Figure 27. Transduced N1ICD binds endogenous RBP-Jk protein in 
cardiomyocytes. 
Detergent solubilized proteins from rat cardiomyocytes transduced with AAV6-N1ICD were 
immunoprecipitated with anti-Myc tag antibody and analyzed by Western blot using anti-
RBP-Jk antibody.  
 
We then analyzed the effect of Notch1 pathway stimulation as an inducer of 
neonatal cardiomyocyte proliferation, evaluating the BrdU incorporation capacity of 
transduced cells in culture. In the case of AAV6-N1ICD-transduced cardiomyocytes, 
the fraction of -actinin+, BrdU+ cells was 14.5% at day 3 and 18.7% at day 7, to 
be compared with 9.4% and 4.1% in cells transduced with a control AAV6 vector. 
Instead, proliferation did not increase at day 3 in cells transduced with AAV6-sJ1, 
however it was remarkably higher than the control at day 7 (15.7% proliferating 
cells; P<0.01; Fig.28A for representative images, 28B for quantification). These 
different kinetics most likely reflect the requirement for soluble Jagged1 to 









Figure 28. Stimulation of Notch pathway through AAVs expands the proliferative 
potential of neonatal cardiomyocytes.  
(A) Representative images of cultured neonatal rat cardiomyocytes at days 3 and 7 of culture 
after transduction with a control AAV6 (a and b respectively), AAV6-N1ICD (c and d) or 
AAV6-sJ1 (f and g). Panels e and h show magnifications of the boxed areas in d and g, 
respectively. White arrows point at cardiomyocyte nuclei positive for BrdU. Scale bar 100 µm 
(a, b, c, f, d and g); 30 µm (e and h). 
(B) Quantification of neonatal cardiomyocyte proliferation at days 3 and 7 after transduction 
with a control AAV6 vector, AAV6-N1ICD or AAV6-sJ1. Shown are the means±sem of at least 
three independent experiments. *: P<0.05;**: P<0.01. 
 
BrdU is incorporated in the nascent DNA during the S phase of the cell cycle, 
therefore BrdU positivity is a marker of DNA replication, not necessarily of cell 
proliferation. To demonstrate that Notch1 stimulation also triggers mitosis and 
cytokinesis, we performed additional immunofluorescence staining to detect 
positivity for histone 3 serine 10 phosphorylation (a marker of mitosis, Fig.29A for 
representative images at day 7 and 29B for quantification) and for the localization 
of Aurora B kinase in midbodies (showing cytokinesis, Fig. 29C for representative 
images at day 7 and 29D for quantification). At day 7, both vectors were able to 
significantly increase the number of cardiomyocytes positive for both markers of cell 
cycle progression, showing that Notch pathway stimulation is able to lead 








Figure  29.  AAV6-N1ICD or AAV6-sJ1 transduction increases mitosis and 
cytokinesis of neonatal cardiomyocytes. 
(A) Representative images of rat neonatal cardiomyocytes transduced with the indicated 
vectors and analyzed, at day 7, by immunofluorescence against histone 3 phosphorylated on 
serine 10 (pH3; red). Cardiomyocytes are stained in green with an anti--actinin antibody; 
nuclei are visualized in blue by DAPI. The leftmost panels show image splitting. Arrows point 
at mitotic cardiomyocytes. Scale bar 100 µm. 
(B) Quantification of pH3+ cardiomyocytes. Shown are the means ± sem of at least three 
independent experiments.  *: P<0.05. 
(C) Representative images of rat neonatal cardiomyocytes transduced with the indicated 
vectors and analyzed, at day 7, by immunofluorescence against Aurora B (red). 
Cardiomyocytes are stained in green with an anti--actinin antibody; nuclei are visualized in 
blue by DAPI. Arrows point at midbodies. Scale bar 30 µm. 
(D) Quantification of midbodies in cardiomyocytes. Shown are the means ± sem of at least 










To better characterize the Notch1 pathway signaling cascade upon transduction with 
AAVs, we performed a series of experiments in neonatal cardiomyocytes in the 
presence or absence of the γ-secretase inhibitor DAPT, which blocks the last step of 
processing of the endogenous Notch receptor, preventing its release into the 
cytoplasm. This experimental strategy allowed us to distinguish between the Notch 
signaling downstream the endogenous receptor, blocked by DAPT treatment, and 
the signaling activated by the exogenously expressed AAV6-N1ICD, directly acting in 
the nucleus, therefore insensitive to γ-secretase inhibition. 
Neonatal cardiomyocytes, transduced with either AAV6-N1ICD or AAV6-sJ1 were 
transfected, at days 2 or 6, with a plasmid expressing the Firefly Luciferase under 
the control of either the Hes1 promoter (Fig.30A, panels a and b) or of a synthetic 
promoter containing 4xRBP-Jk responsive sites (Fig.30A, panels c and d); 
Luciferase activity was measured 24 hours after transfection. Both AAVs were able 
to induce transgene expression at day 7, while only AAV6-N1ICD significantly 
stimulated activity at day 3, paralleling the different vector kinetics. DAPT treatment 
was effective in abolishing AAV6-sJ1 mediated Hes1-transcription, while it was 
largely ineffective on AAV6-N1ICD-driven signaling. These results show that the 
AAV6-sJ1 molecule activates the endogenous intracellular Notch1 signaling cascade, 
while the AAV6-N1ICD protein directly acts on the transcriptional machinery to 
activate the Notch1 pathway. A superimposable effect of DAPT was found by 
analyzing cardiomyocyte proliferation upon AAVs transduction: only AAV6-sJ1-
transduced cardiomyocytes showed a marked decrease in BrdU positivity at day 7 in 
the presence of DAPT (Fig.30B), showing that the effect driven by AAV6-N1ICD 









Figure 30. The effects of AAV6-N1ICD are not mediated by endogenous Notch1 
receptor signaling. 
(A) Neonatal rat cardiomyocytes were transfected with either a Hes1-Luciferase or a 4xRBP-
Jk-Luciferase reporter constructs (panels a-b and c-d respectively) and analyzed at days 3 or 
7 (panels a-c and b-d respectively). Transfection efficiency was standardized by co-
transfecting a constitutively expressed Renilla Luciferase reporter. The histograms show 







 (B) Quantification of BrdU incorporation in neonatal rat cardiomyocytes at days 3 and 7 
after transduction with either AAV6-N1ICD or AAV6-sJ1, in the presence of DAPT or in 
control condition. Shown are the means ± sem of at least three independent experiments.  
*: P<0.05; **: P<0.01 vs. control. 
 
To verify whether Notch target gene expression is stimulated by AAV transduction, 
we analyzed their expression levels in day 3- and day 7-cultured neonatal 
cardiomyocytes transduced at day 0 with either AAV6-N1ICD or AAV6-sJ1. These 
levels were found to parallel the trend of cardiomyocyte proliferation, with AAV6-
N1ICD already acting at day 3 on some targets, while both vectors were able to 
significantly stimulate target gene expression at day 7 (Fig.31). Activation of the 
Notch pathway by AAV6-N1ICD at days 3 and 7 and AAV6-sJ1 at day 7 also resulted 
in the increase of endogenous Notch1 expression, consistent with the existence of a 
positive feed-back loop by which Notch activates its own gene expression [426].  
 
Figure 31.  AAV-mediated transduction stimulates Notch1 target gene 
transcription.  
Transcription level of Notch1 and its target genes in neonatal rat cardiomyocytes analyzed at 
days 3 and 7 after AAV6 vector transduction. Shown are the means±sem of at least three 







We then characterized the chromatin environment at the Notch responsive 
promoters in the presence of Notch pathway constitutive stimulation. Chromatin 
immunoprecipitation experiments were performed in neonatal cardiomyocytes 
cultured for 3 or 7 days and transduced contextually to plating with either AAV6-
N1ICD or AAV6-sJ1. In cells transduced with either of the two Notch-stimulating 
vectors, the chromatin at the analyzed Notch1 responsive genes was significantly 
more acetylated at day 7 than in control-treated cardiomyocytes (Fig.32A). On the 
contrary, the amount of chromatin marked by H3K27me3 and the Ezh2 promoter 
occupancy, which increased in control conditions at day 7, remained stable in the 
transduced cells (Fig. 32B and 32C respectively).  
 
Figure 32. AAV-mediated Notch activation maintains chromatin open at Notch 
target gene promoters. 
(A - C) ChIP analyses for Notch1 and its target gene promoters in control-infected 
cardiomyocytes (light grey line), or cardiomyocytes transduced with AAV6-N1ICD (black line) 
or AAV6-sJ1 (dark grey line) at days 3 and 7 after transduction. Values are normalized over 
the results at day 3. Antibodies were against H3panAc (A), H3K27me3 (B) and Ezh2 (C). 










We also verified that the Notch pathway stimulation was not affecting Ezh2 
expression, to rule out the possibility that the low Ezh2 occupancy at Notch 
responsive promoters was a mere consequence of a decreased expression or 
repressed transcription of Ezh2 induced by Notch activation. RT-PCR experiments 
confirmed that the levels of the endogenous Ezh2 did not change upon AAV 
transduction neither in day 3 nor in day 7 cardiomyocytes, therefore confirming that 
the delayed recruitment of Ezh2 at Notch target gene promoters when Notch 
pathway was exogenously activated by AAVs was not induced by a reduction in Ezh2 
expression level (Fig.33). 
 
Figure 33. Analysis of Ezh2 expression level after exogenous Notch pathway 
activation. 
Transcription levels of Ezh2 in neonatal rat cardiomyocytes analyzed at days 3 and 7 after 
AAV6 vector transduction. Data are expressed to cellular HPRT mRNA levels. Shown are the 
mean±sem of at least three independent experiments. *: P<0.05; **: P<0.01. 
 
Recent evidences have highlighted an important role of Polycomb in the regulation 
of cardiomyocyte proliferation during heart development [427-428]. To further prove 
the role of PcG-mediated transcriptional silencing at Notch responsive genes, we 
treated cardiomyocytes with the specific Ezh2 inhibitor GSK126. These experiments 
were performed in various conditions: when the cells were analyzed at day 3, the 
drug was administered for 2 days before fixation and DMSO was used as a control 
(panel A, condition a-a’-b). For the analysis at day 7, the drug was added for 2 days 







action between days 3 and 7 of culture (condition e), and DMSO was added as a 
control. Since GSK126 efficacy was demonstrated only in a panel of lymphoma cell 
lines [429], we needed to characterize its effect and determine the working 
conditions in our experimental settings. We therefore analyzed the efficacy of 
GSK126 in inhibiting Ezh2 action on neonatal cardiomyocytes by checking the total 
level of H3K27me3 in our experimental conditions. In Western blot experiments, we 
detected a decrease of the total level of H3K27me3 upon GSK126 treatment for 
either 2 or 4 days, demonstrating its effect on cultured cardiomyocytes (Fig.34A 
and B).  
 
Figure 34. The Ezh2 inhibitor GSK126 is able to reduce the total level of 
H3K27me3. 
(A) Western blot analysis of H3K27 trimethylation levels in day 3 and day 7 cardiomyocytes 
in the experimental conditions as indicated (a’ and c’ correspond to the DMSO vehicle 
control). Total Histone H3 is shown as a loading control.  
The blot is representative of at least three independent replicates. 








We then analyzed the effect of Ezh2 inhibition on cardiomyocyte proliferation. At day 
3, the addition of the drug had no significant effect on proliferation, nor it acted 
synergistically with AAV6-N1ICD to boost proliferation (Fig.35, panels a and b). This 
can be explained by the fact that, at day 3, Ezh2 is not strongly active at Notch-
related promoters. When GSK126 was added for 2 days before fixing the cells at day 
7, the inhibition of Ezh2 activity had a proliferative effect similar to the stimulation of 
the Notch pathway (Fig.35, panel d), but no strong synergistic effect was detected 
in the presence of AAV6-N1ICD. When cultured cardiomyocytes were treated for 4 
days with GSK126 between days 3 and 7, the inhibition of Ezh2 in the time frame 
when the chromatin at Notch target genes passes from active to repressive 
transcriptional state synergized with Notch pathway stimulation mediated by AAV6-
N1ICD transduction, reaching 22.2% of BrdU+ cardiomyocytes (Fig.35, panel e), 
indicating that inhibition of the establishment of a repressive chromatin environment 
and stimulation of Notch pathway can cooperate to promote cardiomyocyte 
proliferation.  
 
Figure 35. The Ezh2 inhibitor GSK126 synergizes with Notch pathway stimulation 
in promoting cardiomyocyte proliferation. 
Quantification of neonatal cardiomyocyte proliferation (BrdU incorporation) in the indicated 
experimental conditions.  
a-b: analysis at day 3, after AAV6-Control or AAV6-N1ICD transduction at day 0 and GSK126 
treatment as indicated. c-e: analysis at day 7. Shown are the means±sem of at least three 







AAV-MEDIATED NOTCH PATHWAY ACTIVATION DOES NOT 
STIMULATE HEART REGENERATION IN ADULT MICE 
AFTER MYOCARDIAL INFARCTION 
 
Since these results indicate that gene-transfer-mediated Notch pathway stimulation 
can significantly expand the proliferative capacity of neonatal cardiomyocytes, 
maintaining an open chromatin conformation at the Notch-responsive genes and 
thus sustaining high levels of transcription, we decided to test if Notch pathway 
stimulation could be effective in vivo to promote tissue regeneration after myocardial 
infarction (MI). To do so, we performed myocardial infarction through the ligation of 
the left anterior descending coronary artery in adult CD1 mice. The animals were 
contextually injected with AAV9 vectors encoding N1ICD or sJ1 in the peri-infarct 
zone or with AAV9-Control vector (Fig.36).  
 
Figure 36. Scheme of the in vivo experiment. 
 
The efficiency of transduction was assessed at DNA level through competitive PCR at 







day 7, decreased at day 14, remaining constant until 60 days after transduction 
(Fig.37A). The transgene expression efficiency was evaluated at both mRNA and 
protein levels (Fig.37B and 37C respectively), proving that the transgenes were 
detectable throughout the length of the experiment. 
 
Figure 37. AAV9-mediated transgene expression is effective till 60 days post 
transduction.  
Quantification of neonatal viral genomes (A), levels of mRNA transgene expression (B) and 
of protein transgene expression (C) in mouse hearts at different times after intracardiac 
injection of AAV9-N1ICD, AAV9-sJ1 or AAV9-Control, the last containing an empty MCS (n=3 
per group). 
 
Contrary to our expectation, when we analyzed the functional parameters of 
transduced animals through echocardiography, we could not detect any significantly 
improved cardiac performance in mice transduced with either vector. In particular, 
we did not appreciate any improvement of ejection fraction (LVEF, Fig.38A), 
fractional shortening (LVFS, Fig.38B), anterior wall thickening (LVAWT, Fig.38C), 
systolic and diastolic anterior wall thickness (LVAWT-s and LVAWT–d, Fig.38D and 
38E respectively) in mice transduced with AAV9-N1ICD, while a slightly better 
outcome was detected in AAV9-sJ1 treated animals, but this beneficial effect in any 
case did not reach statistical significance. The absence of a regenerative response 
was confirmed also at the histological level. After Masson trichrome staining to 
visualize the scar area in heart sections, we could not detect any reduction in the 
scar size in the transduced animals (Fig.38F for representative images, Fig.38G for 








Figure 38. Stimulation of the Notch pathway  fails to improve myocardial function 
and to induce repair after myocardial infarction. 
(A-E) Evaluation of cardiac function at different times after MI in mice transduced with 
AAV9-Control, AAV9-N1ICD or AAV9-sJ1. The analyzed parameters are left ventricular 
ejection fraction (A), fractional shortening (B), anterior wall thickening (C), systolic anterior 
wall thickness (D) and diastolic wall thickness (E). n=10-12 per group; P= n.s. Dashed lines 
indicate the average value of non-infarcted animals. 
(F and G) Representative images of Masson trichrome staining (F) and quantification of 
infarct size (G) at 7 and 60 days after MI in adult mice injected with AAV9-Control, AAV9-








AAV-MEDIATED NOTCH PATHWAY ACTIVATION DOES NOT 
INDUCE ADULT CARDIOMYOCYTE PROLIFERATION IN 
VITRO 
 
To understand the cause of the lack of action of the Notch pathway activation in 
vivo in the adult mice, we moved back to an in vitro system of adult cultured 
cardiomyocytes and tested the effect of Notch stimulation on these cells. We first 
needed to assess whether the AAV6 serotype was able to transduce adult 
cardiomyocytes as efficiently as neonatal cells in vitro. Adult ventricular 
cardiomyocytes were extracted by the Langendorff perfusion system, transduced 
with AAV6-EGFP and analyzed for the positivity for -actinin and GFP. In the 
absence of serum, adult cardiomyocytes were efficiently transduced by AAV6 
reaching 60% of GFP positivity. When cultured with serum, which is required for 
their proliferation, transduction efficiency was around 40% (Fig.39A for 
representative images, Fig.39B for quantification). 
 
Figure 39. Transduction efficiency of adult cardiomyocytes by AAV serotype 6 
vectors.  
(A) Top panel: contrast phase representative images of adult rat cardiomyocytes cultured in 
absence of FBS at days 4, 5 and 6 after AAV6-EGFP transduction. Bottom panel: 
Representative immunofluorescence stainings of adult rat cardiomyocytes cultured in 







(B) Quantification of GFP+ adult cardiomyocytes after transduction with AAV6-EGFP vector in 
the absence or presence of FBS in the culture medium. 
 
To investigate the effect of the Notch pathway stimulation on adult cardiomyocytes 
proliferation, we established a culture protocol following the same experimental 
conditions used for neonatal cells. In the presence of 5% of fetal bovine serum, 
adult cardiomyocytes undergo a dedifferentiation process, which leads to a radical 
morphological change in the adult cardiomyocytes, which lose their rod-like shape, 
but still are incapable of BrdU incorporation in the absence of stimuli (Fig.40A, 
panel a). Using these settings, the day after plating adult cardiomyocytes were 
transduced with either AAV6-N1ICD or AAV6-sJ1 and kept in culture for 9 days; 48 
hours before fixation, BrdU was added to the medium. In these conditions, neither 
of the two vectors was able to stimulate BrdU incorporation (Fig.40A, panels c and 
e). When de-differentiated, adult cells were transduced with AAV6 encoding for miR-
199a or miR-590 a BrdU pulse of 48 hours resulted in 5.7% and 16.2% of BrdU+ 
positive cardiomyocytes respectively (Fig.40A, panels g and i; Fig.40B for 
quantification), meaning that it is possible to re-activate proliferative pathway in 
adult cells, but not through direct stimulation of the Notch pathway. Adult 
cardiomyocytes transduced with miRNAs were also found positive for other cell cycle 








Figure 40. Notch1 pathway stimulation fails to induce adult cardiomyocyte re-
entry into the cell cycle. 
(A) Representative images of adult rat cardiomyocytes at day 9 of culture upon transduction 
with a control AAV6 (panel a), AAV6-N1ICD (c), AAV6-sJ1 (e), AAV6-miR-199a (g) or AAV6-
miR-590 (i). Panels b, d, f, h and j show magnifications. White arrows point at 
cardiomyocyte nuclei positive for BrdU. Scale bar 100 µm.  
(B) Quantification of adult cardiomyocyte proliferation after transduction with the indicated 
AAV6 vectors. Shown are the means±sem of at least three independent experiments.  
(C) Representative images of adult rat cardiomyocytes at day 9 of culture upon transduction 
with a AAV6-miR-199a or AAV6-miR-590. Cardiomyocytes are stained in green with an anti-
-actinin antibody; nuclei are visualized in blue by DAPI. In the top panel red staining 
represents Ki67, in the bottom panel it represents histone 3 serine 10 phosphorylation (pH3). 












To further confirm that proliferation of adult cardiomyocytes does not involve the 
Notch1 signaling cascade, we evaluated the Notch target gene expression levels in 
adult cardiomyocytes transduced with either AAV6-miR-199a or AAV6-miR-590: none 
of the analyzed genes showed transcriptional upregulation, meaning that the 
proliferative program which is reactivated by selected miRNAs in the adult cells does 
not involve Notch signaling (Fig.41).  
 
Figure 41. Notch target genes are not upregulated in proliferative adult 
cardiomyocytes. 
Transcription levels of Notch1 and its indicated target genes in adult rat cardiomyocytes 
analyzed at day 9 after transduction with a control AAV6, AAV6-miR-199a or AAV6-miR-590. 
Data are expressed to cellular HPRT mRNA levels. Shown are the mean±sem of at least 







NOTCH TARGET GENE PROMOTERS ARE METHYLATED AT 
THE DNA LEVEL IN ADULT CARDIOMYOCYTES 
 
To better understand the molecular cause for the lack of Notch stimulation in adult 
cells, we analyzed the DNA methylation pattern at Notch target gene promoters, as 
DNA methylation in the promoters is commonly associated with permanent 
transcriptional silencing [338]. For this purpose, we performed bisulfite sequencing 
analysis on genomic DNA extracted from neonatal cardiomyocyte kept in culture for 
3 or 7 days, and from adult cardiomyocytes. Bisulfite sequencing analysis allows one 
to distinguish whether CpG dinucleotides are methylated or not in the DNA. Through 
bioinformatics analysis, we identified CpG-rich regions in the Notch target gene 
promoters. We performed bisulfite treatment on genomic DNA, followed by PCR in 
different areas of the CpG-rich regions spanning the transcriptional start site (TSS). 
Then we cloned and sequenced 8 different clones for each PCR amplified fragment.  
Notch1 promoter displayed a strong increase of DNA methylation level paralleling 
the exit of cardiomyocytes from the cell cycle. At day 3, the extent of DNA 
methylation at the Notch1 gene promoter was relatively low (2.5% of the CpG 
dinucleotides analyzed upstream the TSS and 1.8% downstream the TSS. Each row 
represents a single analyzed DNA clone; white and black circles show unmethylated 
and methylated CpG dinucleotides, respectively), markedly increased in day 7 cells 
(20.0% and 4.9%, respectively) and peaked in adult cardiomyocytes (36.2% and 
12.9% respectively; Fig.42A). The same trend was also maintained in the Hes1 
gene, where, at day 3, 2.7% of the CpGs in the analyzed region upstream the TSS 
scored positive for methylation and 2.3% in the region downstream the TSS. These 
levels rose to 4.2% and 8.6% at day 7 and to 15.3 and 22.7%, respectively, in adult 
cardiomyocytes (Fig.42B). Analogous results were obtained for Hey1 and Hey2, 
even if less pronounced, overall showing increased methylation in day 7 and adult 







potential interest, the Cyclin D1 promoter showed a different methylation pattern, 
with scattered methylation also occurring in day 3 samples in the more upstream 
GC-rich region (2.5 kb upstream the TSS), not correlating with transcriptional 
silencing, while the CpG-rich regions close to the TSS (explored by primer set D) 
remained unmethylated also in the adult (Fig.42E). This result is consistent with the 
requirement for Cyclin D1 re-expression when adult cardiomyocyte proliferation is 
induced by various stimuli, including miRNAs. 
We also performed the same analysis of the TSS regions of GAPDH, a housekeeping 
gene, and GFAP, a glial gene silenced in cardiomyocytes, considering them as 









Figure 42. Notch1 and Hes1 promoters in non proliferative cardiomyocytes show 
markedly increased levels of DNA methylation. 
(A-G) Results of bisulfite sequencing data from DNA obtained from day 3, day 7 and adult 
rat cardiomyocytes using primer pairs encompassing the indicated promoter regions of the 
Notch1 (A), Hes1 (B), Hey1 (C), Hey2 (D), Cyclin D1 (E), GAPDH (F) and GFAP (G) genes 







DNA methylation is widely associated to transcriptional repression, but recently few 
cases of opposite behavior have been identified [430]; we therefore needed to 
confirm that in the genes of our interest DNA methylation spanning the TSS 
effectively corresponds to transcriptional silencing. We performed an in vitro 
methylation assay, in which different constructs containing Notch1, Hes1, Hey1 and 
Hey2 promoters were cloned upstream the Luciferase reporter gene; the empty 
vector pGL3 was used as a control. These plasmids were in vitro methylated using 
SssI CpG methyltransferase and the methyl donor S-adenosyl-methionine (SAM). 
They were subsequently transfected in neonatal rat cardiomyocytes and Luciferase 
activity was analyzed at days 3 or 7 of culture (Fig.43A and 43B respectively). We 
observed that DNA methylation markedly decreased Luciferase activity, further 
supporting the evidence that DNA methylation correlates with repressed 
transcription at Notch target gene promoters. 
 
Figure 43. Effect of promoter methylation in Luciferase reporter assays.  
(A and B) Rat neonatal cardiomyocytes were transiently transfected with SssI-methylated 
(grey bars) or unmethylated (white bars) plasmids containing either Notch1 full length or the 
Notch1 core region promoter, Hes1, Hey1, Hey2 driving expression of Firefly Luciferase. As a 
control of the methylation reaction, each plasmid DNA vector was also treated with equal 
amounts of methylating enzyme, but without the methyl group donor SAM (black bars). 
Luciferase activities were normalized for transfection efficiency by cotransfection of an 







Values are the mean ± sem obtained from three independent experiments.  **: P< 0.01. 
Reporter gene expression was analyzed at days 3 (A) and 7 (B). 
 
In vitro DNA methylation efficiency was assessed comparing DNA sensitivity to the 
MspI/HpaII restriction enzyme isoschizomers: in the presence of the methyl donor 
SAM, the methylation-sensitive enzyme HpaII was unable to digest the plasmid, 
confirming the efficient methylation of the constructs (Fig.44). 
 
Figure 44. Control of the in vitro methylation efficiency. 
  
To further demonstrate the role of DNA methylation as an important regulator of 
Notch pathway silencing, we cultured neonatal cardiomyocytes in the presence of 5-
Aza-2´deoxycytidine (AzaC), a nucleotide analog that prevents DNA methylation. 
AzaC treatment is effective as DNA methylation inhibitor during the establishment of 
the methylation pattern, while it cannot revert DNA methylation when it is already 
present. Therefore, we performed the experiment in neonatal cardiomyocytes, in 
order to prevent DNA methylation deposition, and not in adult cells, in which DNA 
methylation is already present, since AzaC treatment would have been ineffective. 
We treated cultured cardiomyocytes for 48 hours between days 1 and 3 of culture 
by adding 5 µM AzaC in the medium. We first wanted to analyze whether this 
treatment affected the DNA methylation pattern. For this purpose, we performed 







AzaC. We analyzed the methylation pattern of Notch1, Hes1 and GFAP (Fig.45 A, B 
and C respectively), and we detected a strong reduction at the DNA methylation 
level compared to the control (summarized in Fig.45D).  
 
Figure 45. AzaC treatment decreases DNA methylation in the analyzed genes. 
(A-C) Results of bisulfite sequencing data from DNA obtained from day 7 cardiomyocytes 
treated, between day 1 and day 3, with 5 μM AzaC. Eight different clones are shown for 
Notch1 (A), Hes1 (B) and GFAP (C). 
(D) Summary table showing differences in DNA methylation found in day 7 cardiomyocytes 
comparing untreated cells (data shown in Fig.20) and cells treated with AzaC. 
 
We then analyzed the effect of AzaC treatment on cardiomyocyte proliferation at day 
7. By itself, AzaC supplementation to the culture medium is able to strongly 
stimulate BrdU incorporation in cardiomyocytes (which reaches 15% of BrdU+, -







silencing of many pathways controlling proliferation activity in the fetal life, later 
downregulated in the postnatal life. When we transduced AzaC-treated 
cardiomyocytes with AAV6-N1ICD, we detected a strong synergistic effect between 
Notch stimulation and AzaC treatment, with 25.9% of cardiomyocytes which scored 
positive for BrdU at day 7. The most relevant result, however, was the effect of 
AzaC in creating a favorable chromatin environment for the NICD driven 
transcriptional regulation of cardiomyocyte proliferation. We transduced cultured 
cardiomyocytes at day 4 with AAV6-N1ICD, and in this case the N1ICD transgene 
was less effective in triggering cardiomyocyte proliferation compared to cells 
transduced at day 0 (10.9% vs. 17.2%). In the presence of AzaC, even in case of 
transduction at day 4, cardiomyocytes reached 26.2% of BrdU positive cells, 
consistent with the conclusion that impeding the establishment of de novo 
methylation favors the effect of N1ICD (Fig.46). Therefore, we can conclude that 
exit from the cell cycle of cardiomyocytes correlates with the permanent repression 
of Notch1 target genes, therefore providing a molecular explanation for the 
inefficacy of the treatments aimed at reactivation of Notch pathway by gene transfer 








Figure 46. Inhibition of DNA methylation synergizes with Notch activation in 
stimulating cardiomyocyte proliferation.  
Number of proliferating cardiomyocytes analyzed at day 7 in cultures transduced at day 0 or 
day 4 with AAV6-N1ICD and treated with AzaC at days 1-3 when indicated. Shown are the 
means±sem of at least three independent experiments. **: P<0.01. “Control” (white bar) in 
the first group of two from top corresponds to untreated cells; “Control” in the lower two 











There is a pressing need to develop novel therapeutic approaches aimed at 
generating new contractile tissue in patients with myocardial damage. In mammals, 
the heart tries to react to the loss of cardiomyocytes with a partial regenerative 
attempt [25-26], but the prevailing mechanism in response to myocardial damage is 
scarring. Many approaches have been used to achieve heart regeneration via the 
induction of cardiomyocyte proliferation [32-37]. My thesis is in this line of research, 
studying a possible regenerative role of the Notch pathway in the heart. 
The Notch pathway is a widely known regulator of proliferation during many 
developmental processes and it plays a crucial role during cardiogenesis [192]. It is 
well established that cardiomyocytes are actively proliferating in the fetal and early 
neonatal life, but lose their proliferative potential shortly after birth. Previous results 
from our lab [196] and others [203] reported an important role of Notch signaling in 
the control of neonatal cardiomyocyte proliferation. In details, we noticed that at 
birth a relevant fraction of immature, still proliferating cardiomyocytes are positive 
for Notch1 expression, while this population is lost over time, since in the adult the 
fraction of proliferative cardiomyocytes is significantly lower. In a model of rat 
cardiomyocyte culture, we can recapitulate the exit of cardiomyocytes from the cell 
cycle, paralleled by the loss of Notch signaling. In vitro, the sustained activation of 
this pathway through a gene transfer approach using an AAV coding for the active 
form of Notch1 (N1ICD) or through the stimulation with the soluble form of the 
ligand Jagged1 (sJ1), is able to expand the fraction of immature ventricular 
cardiomyocytes still capable of proliferation. Accordingly, the block of Notch1 
signaling significantly reduces cardiomyocyte proliferation potential [196]. In line 
with these evidences, exogenous administration of Notch2-ICD was demonstrated to 







the cell cycle regulator Cyclin D1 but also triggers Cyclin D1 import in the nucleus, 
therefore confirming the relevance of Notch pathway in cardiomyocyte proliferation 
control [203].  
In Zebrafish, upon the resection of up to 20% of the ventricle, cardiac regeneration 
is efficiently achieved through adult cardiomyocyte proliferation. This process is 
controlled by the Notch pathway, which is strongly activated both in the 
endocardium and in the epicardium of amputated Zebrafish hearts during the 
healing process. The block of the Notch signaling profoundly impairs the 
regenerative capacity of the Zebrafish heart, decreasing the fraction of proliferative 
cardiomyocytes and inhibiting the atrial to ventricular transdifferentiation process. 
Interestingly these findings demonstrate the existence of a specific regenerative 
pathway, different from the embryonic heart development program [96, 99-101].  
Given the above reported evidences, we wondered whether the Notch pathway 
could drive cardiomyocyte proliferation in adult rodents as well as it happens in the 
Zebrafish heart. The rationale behind this approach was that the genetic program 
downstream its activation could eventually lead to myocardial regeneration after 
damage, therefore supporting the exploiting of Notch1 as a therapeutic tool for 
cardiac regeneration.  
The in vitro studies involved a comparative analysis of the Notch pathway in 
neonatal and adult cardiomyocytes. Our culture model of neonatal cardiomyocytes 
reproduces in vitro the withdrawal of myocytes from the cell cycle, which happens in 
vivo during the first week after birth: we considered 3 days-old cardiomyocytes as 
“proliferative” and 7 days-old cardiomyocytes as “non proliferative”. In order to have 
a more physiological model for adult cells, we optimized the Langendorff perfusion 
system to purify and culture cardiomyocytes from adult rats.  
We show that Notch pathway sustains active cardiomyocyte proliferation and that 
cardiomyocyte loss of proliferation capacity together with their exit from the cell 







correlates with the decreased transcriptional level of Notch target genes. In this 
context we have analyzed the genes described to be downstream of Notch signaling 
during heart development (as basic helix-loop-helix transcription factors Hes1, Hey1 
and Hey2) and Cyclin D1, important regulator of cell cycle controlled by Notch in 
cardiomyocytes [203, 431] and Notch1 itself [426].  
The regulation of Notch pathway involves a variety of epigenetic modifications 
occurring at the target gene promoters [112]: the presence of NICD contribute to 
the formation of a complex promoting active chromatin transcription, while after the 
degradation of NICD, in order to switch off the transcription of the target genes, a 
transcriptional repressor complex is recruited. We further characterized the 
epigenetic modifications occurring in cardiomyocytes at Notch target gene 
promoters: we observed that, in neonatal cardiomyocytes, these chromatin regions 
are in an open and transcriptionally permissive conformation, supporting the 
correlation between the high levels of transcription with the proliferative capacity of 
the cells. The analyzed promoters are characterized by the presence of broad marks 
of active transcription, as pan-acetylation of histone 3 and H4K3 trimethylation [432-
433], consistent with the reported data, stating the presence in the NICD activator 
complex of different HATs [112, 116] and the association of H3K4 trimethylation 
with NICD-driven active transcription [365, 369]. 
Interestingly, one week after birth and in adult cells, the presence of the same 
active chromatin marks is strongly decreased, while marks of repressive chromatin 
associated to Polycomb mediated silencing [268, 272], as H3K27me3 and the 
promoter occupancy by the methylating enzyme Ezh2 [266, 274, 282] are enriched. 
These data support the idea that at, Notch responsive genes, the chromatin 
environment passes from a transcriptionally active to an inactive state parallel to 
cardiomyocyte terminal withdrawal from the cell cycle and that this repressive 







Polycomb-mediated silencing of Notch pathway is also reported in other models: 
during development in Drosophila, where PRC1 binds to multiple components of 
Notch signaling pathway to control proliferation [371], in dystrophic skeletal muscle, 
where TNF suppresses Notch1 promoting the recruitment of Ezh2 to the Notch-
responsive promoters [377] and in B cell acute lymphoblastic leukemia, where Notch 
and its target genes are less expressed due to epigenetic regulation at the 
promoters, involving decreased H3K4 methylation and increased H3K9 and H3K27 
methylation [378]. Moreover, a genome wide study aimed to analyze the location of 
H3K27 trimethylation in embryonic fibroblasts, identified the Notch signaling as one 
of the pathway regulated by PcG-mediated silencing [281]. Interestingly, PRC2 
complex has been reported to interact with H3K4 demethylases [434]. In the 
developing myocardium, endothelial deletion of Jarid2, a member of the Jumonji 
family of proteins which associates with the PcG complex to modulate its function 
[435-436], derepresses endocardial Notch1 expression [373]. In addition, deletion of 
Ezh2 in cardiac progenitors is known to cause postnatal myocardial pathology [428]. 
The results shown in this Thesis appears to be fully consistent with these findings.  
After assessing the repressive chromatin environment at Notch target genes in fully 
differentiated cardiomyocytes, we wondered whether it was possible to revert the 
silencing using a gene transfer approach, exploiting the Adeno Associated viral 
(AAV) vector technology. 
AAV vectors are excellent tool to achieve long lasting transgene expression in 
postmitotic organs in vivo, being capsid 9 the most efficient serotype to achieve high 
transduction levels in the heart in vivo [407] as well as a very interesting tool to 
efficiently transduce cardiomyocytes in vitro, achieved using serotype 6 capsid 
[437]. Therefore we exploited AAV technology to force Notch pathway activation. 
We designed two AAV vectors, able to activate the Notch pathway through different 
strategies: the AAV-N1ICD codes for the intracellular domain of Notch1, which can 







activator complex, turning on the transcription of Notch target genes irrespective of 
the endogenous level of Notch1 expression in the transduced cells. The vector 
encoding for the soluble form of Jagged1 instead targets a different cell population, 
since it activates signaling only in the cells that express endogenous Notch1 
receptor, and in which Notch activation can create a feedback loop stimulating its 
own expression. Moreover, in order to activate signaling, the Jagged1 transgene 
needs to reach a minimum concentration in the medium, necessary for the 
multimerization step required for soluble ligand-mediated activation of Notch 
signaling [438]. This conceptual difference between the two vectors explains their 
different strength and kinetics.  
In neonatal cardiomyocytes, the establishment of repressive chromatin environment 
at Notch target genes was efficiently counteracted by the exogenous activation of 
Notch pathway achieved by AAV-mediated gene transfer using both the NICD and 
soluble Jagged1 transgenes. Transduction correlated with increased transcriptional 
activation of Notch target genes after 7 days of culture, with elevated and prolonged 
proliferative capacity of cardiomyocytes in culture and with the maintenance of a 
transcriptionally competent chromatin environment. Moreover, the synergy in 
sustaining proliferation between Notch pathway stimulation by AAV and Ezh2 
inhibition, which prevents the deposition of Polycomb related repressive marks, 
further strengthened the role of Polycomb-mediated silencing in the establishment of 
a repressor environment at Notch target gene promoters.  
To our disappointment, the AAV-mediated reactivation of the Notch pathway was 
ineffective in vivo in a model of myocardial infarction, where we expected that Notch 
activation, similar to its effect in neonatal cardiomyocytes, would have stimulated 
cardiomyocytes to proliferate, therefore sustaining a regenerative response in the 
infarcted heart. On the contrary of our expectation, no regenerative response, and 
hence no major beneficial effect, was apparent in our vivo experiment. NICD-







transduced animals showed a trend, which was not statistically significant yet, 
towards improved function. We speculate that this marginal effect might be the 
consequence of the action of Jagged1, which is expressed and secreted by the 
transduced cardiomyocytes, on other cell types than cardiomyocytes, for example 
stimulating angiogenesis or modulating the immune system response.  
Interestingly, adult cardiomyocytes are not replicative cells, but they can be induced 
to reenter in the cell cycle in response to a variety of stimuli, including Periostin 
[36], Neuregulin [37], FGF1 together with a p38 inhibitor [34], miR-590 and miR-
199a [39], which have all been shown capable to stimulate DNA synthesis, 
karyokinesis and cytokinesis; the same stimuli, then, also provided benefit after 
myocardial infarction, resulting in improved cardiac functionality and reduced infarct 
size. Therefore, the lack of regenerative response driven by Notch is not due to an 
intrinsic inability of adult cardiomyocytes to proliferate, but to the inefficiency of 
Notch to activate the specific genetic program underlying the proliferative capacity in 
adult cells.  
A molecular explanation for the different behavior of neonatal and adult cells in 
respect to Notch pathway stimulation resides in the different methylation pattern 
found at the DNA level in the Notch target genes. We detected that the DNA 
methylation at these promoters was increased over time, paralleling cardiomyocyte 
exit from the cell cycle and explaining the lack of action in the adult, since DNA 
methylation is commonly associated with gene repression [338]. Interestingly, the 
Cyclin D1 promoter behaved differently at the DNA methylation level, showing no 
clear methylation enrichment from neonatal to adult cardiomyocytes. This result is in 
agreement with the requirement for Cyclin D1 re-expression when proliferation of 
adult cardiomyocytes is triggered by other stimuli. 
The relationship between Polycomb-mediated gene repression and DNA methylation 
is still poorly understood. In many contexts these two occurrences are probably 
mutually exclusive; however in embryonic stem cells, genes marked by H3K27 







potential cooperation between the two mechanisms. During development, the 
silencing process is initiated by Polycomb complexes and, subsequently, long term 
silencing is achieved via DNA methylation, also due to the Ezh2-mediated 
recruitment of Dnmts [327]. Interestingly, this silencing step cascade has been 
reported at the Notch promoter in skeletal muscle cells [377] and in B-cell acute 
leukemia cells [378], where Polycomb mediated silencing induces DNA methylation.  
The literature is rich of reports showing a beneficial effect of Notch signaling 
activation in a variety of models of heart damage. Notch signaling has been reported 
to exert regenerative effect through activation of an epicardial derived cell 
population, which could decrease fibrosis, stabilize the arterial endothelium and 
control angiogenesis [200]. Notch can act on a mesenchymal stromal cell 
population, where it reduces myofibroblast proliferation, while it stimulates cardiac 
precursor cell proliferation [199]; it can recruit bone marrow derived cells in the 
context of heart infarction, where they stimulate neovascularization and infarct size 
reduction [439]; it stimulates progenitor cell population expansion and commitment 
toward mature cardiomyocytes [194, 202]. Remarkably, all these beneficial effects 
appear to act through the stimulation of presumed or demonstrated stem cell 
populations or through the stimulation of the intrinsic capacity of still not fully 
differentiated cardiomyocytes to proliferate. In contrast, our strategy, which was 
based on the stimulation of adult cardiomyocyte proliferation, turned out to be 
ineffectual, but this is not in contrast with previously described data. Notch pathway 
stimulation could still remain a possible tool to expand precursor cell or immature 
cardiomyocyte populations, which could then contribute to heart regeneration; 
moreover, the marginal improvement in cardiac function observed in vivo in the 
animals transduced with AAVsJ1, which can be attribute to paracrine effect, supports 
a possible beneficial effect of Notch1 stimulation in myocardial infarction on other 
cell types than cardiomyocytes. Published work has also reported that the 
conditional overexpression of Notch1 in cardiomyocytes after myocardial infarction in 







which was mainly attributed to the preservation of cardiomyocyte viability and the 
stimulation of angiogenesis, with no evidence of a major regenerative effect [197]. 
This conclusion appears to be fully consistent with our results. 
In conclusion, contrary to other conditions such as brain ischemia [154] and skeletal 
muscle injury [440] in which reactivation of Notch signaling promotes tissue repair, 
attempts at inducing cardiac regeneration after myocardial infarction by the 
reactivation of the Notch pathway in cardiomyocytes by gene transfer appear to be 
ineffective. This observation contrasts with the assumption that tissue regeneration 
in adult organisms has to recapitulate the events occurring during development. A 
parallel situation also exists for other organs. For instance, the satellite cell 
transcription factor Pax7 is required for skeletal muscle regeneration in neonatal 
mice, but is dispensable for regeneration during juvenile and adult stages [441]. In 
both cardiac and skeletal muscle, therefore, it appears that a distinction exists 
between the molecular mechanisms driving development and those responsible for 
further maintenance, expansion and repair of the differentiated tissues.  
The therapeutic exploitation of proliferation mechanisms in adult tissues is still a 








MATERIALS AND METHODS 
 
Animals 
Animal care and treatment were conducted in conformity with institutional guidelines 
in compliance with national and international laws and policies (European Economic 
Community Council Directive 86/609, OJL 358, December 12, 1987). Wistar rats and 
CD1 mice were purchased from Charles River Laboratories Italia Srl and maintained 
under controlled environmental conditions.  
 
Culture of neonatal rat cardiomyocytes 
Neonatal rat ventricular cardiomyocytes were extracted from day 0 or day 1 
newborn Wistar rats, as described previously [196], with minor modifications. 
Briefly, ventricles were separated from atria and great vessels and cut in smaller 
pieces. The dissociation was performed in CBFHH (calcium and bicarbonate-free 
Hanks with Hepes) buffer containing 1.75 mg/ml of trypsin (BD Difco) and 10 µg/ml 
DNAse II (Sigma). Digestions were performed on a stirrer in eight- to ten-10 
minutes steps; after each digestion, the supernatant was collected and trypsin was 
inactivated with Fetal Bovine Serum (FBS, Life Technologies). The collected 
supernatant was centrifuged and the cell pellet was resuspended in the medium 
DMEM (Dulbecco’s modified Eagle medium, Life Technologies) 4.5 g/l glucose 
supplemented with 5% FBS, 20 mg/ml vitamin B12 (Sigma), 100 U/ml penicillin and 
100 µg/ml streptomycin (Sigma). The cells were filtered through a cell strainer (40 
µm, BD Falcon) and then pre-plated on plastic 10 cm dishes for 2 hr at 37° in 5% 
CO2. After the pre-plating step, the cardiomyocyte-containing medium was collected, 
the cells were counted and then plated at the appropriate density on Primaria plates 
(BD Falcon), or on glass slides pre-coated with 0.2% gelatin in PBS. The culture 







When indicated, the Ezh2 inhibitor GSK126 [429] (BioVision; 1 µM) was added to the 
medium for 2 or 4 days. When indicated, 5-Aza-2-deoxycytidine (AzaC; Sigma; 5 
µM) was added to the culture medium for the first 2 days of culture, between day 1 
and day 3, and then removed. When indicated, the γ-secretase inhibitor DAPT (N-
[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, Sigma, 10 μM for 
8 hours) was added. In all the cases, DMSO was used as a control.  
 
Culture of adult rat cardiomyocytes 
Adult ventricular cardiomyocytes from 2-months-old adult female Wistar rats were 
extracted with Langendorff perfusion system. Animals were anesthetized with zoletil 
and xylazine and heparinized with 2 ml of heparin (Sigma) 1000U/ml. The heart was 
cannulated through the aorta and perfused with a perfusion buffer composed of 
NaCl 120.4 mM, KCl 14.7 mM, KH2PO4 0.6 mM, Na2HPO4 0.6 mM, MgSO4-7H20 1.2 
mM, NaHCO3 4.6 mM, Na-Hepes 10 mM, taurine 30 mM, 2,3-butanedione monoxime 
(BDM) 10 mM, glucose 5.5mM (all from Sigma) in H2O pH 7.2. After 5 min, 1 mg/ml 
Liberase TM (Roche) was added to the perfusion buffer for 10-12 min. The heart 
was detached from the apparatus; atria and great vessels were removed and the 
ventricles were cut into smaller pieces. Mechanical digestion was performed 
pipetting up and down the tissue fragments in wash medium (50:50 perfusion 
buffer: DMEM 1g/l glucose). The collected cell suspension was filtered (100 µm cell 
strainer, BD Falcon) and centrifuged at low speed (30 g) 3 min at room 
temperature. The cell pellet was resuspended in wash buffer and then added to the 
BSA gradient prepared with 0.645 g BSA (Sigma) in DMEM 1g/l glucose. The 
separation of cardiomyocytes from other cell types lasted 15 min at room 
temperature. Then the cardiomyocyte pellet was resuspended in ACCT medium, 
composed of 2 g/l BSA, 2 mM L-carnitine, 5 mM creatine, 5 mM taurine, 1 mM BDM 
(all from Sigma), 100 U/ml of penicillin and 100 µg/ml of streptomycin in DMEM 1g/l 
glucose. Cells were plated on Primaria plates coated with Laminin (Sigma) and kept 







fresh ACCT medium to remove cardiomyocytes not attached to the plate. The 
medium was changed 24 hr later with fresh ACCT medium or with DMEM 4.5 g/l 
glucose supplemented with 5% FBS and Vitamin B12.  
RNA isolation and quantitative real-time PCR 
Total mRNA was purified either from cultured neonatal cardiomyocytes at day 3 and 
7 of culture, or from adult cardiomyocytes 3 or 9 days after plating or from total 
heart homogenates. Extracted mRNA (1 µg) was reverse-transcribed using MLV-RT 
(Invitrogen) with random hexamers (10 µM) in a 20 µl reaction, following the 
manufacturer’s instruction. mRNA levels for Notch1, Hes1, Hey1, Hey2, Cyclin D1 
and HPRT genes (primer sequences listed in Primer Table I) were quantified by qRT-
PCR and GoTaq qPCR Mater Mix (Promega). The real-time qPCR program was 
performed with a melting curve dissociation protocol (from 60°C to 95°C), according 
to manufacturer’s instruction. The final dilution of the primers in the reaction was 
900 nm; for each primer set, optimal conditions were established and efficiency of 
the amplification was calculated.   
 
Analysis of protein expression 
For the transgene expression, heart samples were collected at different time points 
after myocardial infarction, homogenized in 1 ml of RIPA Buffer (20 mM Tris-HCl pH 
7.4, 150 mM NaCl, 5 mM EDTA, 0.1% sodium dodecyl sulfate [SDS], 1% Triton X-
100, 1% deoxycholate), supplemented with 90 μg/ml PMSF, 1 mM Na3VO4 (all from 
Sigma) and protease inhibitors (Roche), using Magna Lyser (Roche). After sonication 
and pre-clearing, protein lysate concentration was determined by Bradford Assay 
(Biorad). Equal amounts of proteins were resolved on 6% SDS-PAGE minigels and 
transferred to nitrocellulose membranes (GE Healthcare). Immunoblots were blocked 
in 5% skim milk in TBST (50 mM Tris-HCl pH 7.4, 200 mM NaCl, and 0.1% Tween 
20). Membranes were incubated with primary antibodies overnight and washed in 







membranes for 45 min at room temperature. Proteins were detected with the ECL 
detection kit (GE Health Care Bio-Sciences).  
For the analysis of H3K27 methylation, the same procedure was performed, but 
proteins were resolved on 15% if SDS-PAGE minigels. Membrane stripping was 
performed in stripping buffer (100mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-
HCl pH 6.7) at 56°C for 15 min, followed by extensive washing in TBST.  
To detect the in vivo physical interaction between N1ICD transgene and RBP-Jk, 
1x106 neonatal rat cardiomyocytes, transduced with AAV6-N1ICD, were lysed in IPLS 
buffer (50 mM Tris-HCl pH 7.5, 120 mM NaCl, 0.5 mM EDTA and 0.5% Nonidet P-
40) supplemented with 90 μg/ml PMSF (Sigma) and protease inhibitors (Roche). 
After sonication and pre-clearing, protein lysate concentration was determined by 
Bradford Assay (Biorad). N1ICD was immunoprecipitated from total cell lysates with 
1 mg/ml of monoclonal 9B11 Myc-tag antibody for 2 hr at 4°C with gentle rotation, 
followed by incubation with protein A/G agarose beads (Santa Cruz) for additional 2 
hr. Immunoprecipitates were resolved on 10% SDS-PAGE minigels and transferred 
to nitrocellulose membranes (GE Healthcare). Immunoblots were blocked in 2% BSA 
(Roche) in TBST. Membranes were incubated with RBP-Jk primary antibody 
overnight and washed in TBST. Secondary antibodies were diluted in blocking buffer 
and incubated with the membranes for 45 min at room temperature. Proteins were 
detected with the ECL detection kit (GE Health Care Bio-Sciences).  
The following antibodies were used for Western Blot: anti-Myc 9B11 (2279, 1:1000, 
Cell Signaling), anti-Tubulin (T5168, 1:10000, Sigma), anti-H3K27me3 (ab6002, 
1:1000, Abcam), anti-Histone-H3 (06-755, 1:1000, Millipore), anti RBP-Jk (AB 2284, 
1:1000, Millipore). The following antibody were used as secondary: goat anti-mouse 
conjugated to HRP (P0447, Dako-Cytomation), goat anti-rabbit conjugated to HRP 










Neonatal cardiomyocytes were seeded onto 96-well primary cells culture plates 
(1x104 cells per well) and co-transfected after either 2 or 6 days after isolation with 
0.5 μg of either pHes1 (kindly provided by R. Kageyama, Kyoto University, Japan) or 
4xRBP-Jk-Luc (provided by S.D. Hayward, John Hopkins University School of 
Medicine, Baltimore, MD) reporter plasmids and 0.05 μg pRL-Renilla (which was 
used as a control) using Lipofectamine 2000 transfection reagent (Invitrogen). 24 hr 
after transfection, cells were harvested and both Firefly and Renilla Luciferase 
activities were assayed with the Dual-luciferase reporter assay kit (Promega). The 
value of Firefly Luciferase activity was corrected for the transfection efficiency by 
using the Renilla Luciferase activity in each sample.  
 
Promoter methylation assays 
A series of plasmids were generated, in which the promoter regions of the following 
genes were cloned upstream of the Firefly Luciferase gene: Hes1 [442] (kindly 
provided by R. Kageyama, Kyoto University, Japan), Hey1 [443] (kindly provided by 
Manfred Gessler, Theodor-Boveri-Institut fuer Biowissenschaften, Wuerzburg, 
Germany), Hey2 [118] (kindly provided by Stefano Zanotti, Saint Francis Hospital 
and Medical Center, Hartford, CT) and Notch1 [444] (kindly provided by Warren S. 
Pear, University of Pennsylvania, Philadelphia). Plasmid pGL3 contained an empty 
polylinker (Promega). Each reporter construct (10 µg) was methylated in vitro using 
20 U of SssI methylase (New England Biolabs) in the presence of S-adenosyl-
methionine (160 µM; New England Biolabs) at 37°C for 4 hr, with subsequent 
inactivation of the enzyme at 65°C for 20 min. Mock-methylation reactions were 
performed using the same conditions, but omitting SAM. Complete methylation was 
ascertained by digesting the methylated DNA with an excess (20 U/mg) of restriction 
enzymes HpaII or MspI. All the constructs were purified using Wizard DNA 







Neonatal cardiomyocytes were seeded onto 96-wells primary cells culture plates 
(1x104 cells per well) and co-transfected at either day 2 or 6 with 0.5 μg methylated 
or mock-methylated constructs and 0.05 μg pRL-Renilla (which was used for 
standardization) using Lipofectamine 2000 transfection reagent (Invitrogen). 24 hr 
after transfection, cells were harvested and both Firefly and Renilla Luciferase 
activities were assayed with the Dual-luciferase reporter assay kit (Promega). The 
value of Firefly Luciferase activity was corrected for the transfection efficiency by 
using the Renilla Luciferase activity in each sample. 
 
Viral genome quantification through competitive PCR 
DNA was extracted from frozen hearts of transduced animals collected at different 
time points with Blood and Tissue Kit (Qiagen). Competitive PCR was performed as 
previously described [445], using a multicompetitor plasmid carrying a deleted form 
of the cellular gene β-globin flanked by CMV primer sequences to quantify total 
genomic DNA as a reference and AAV vector DNA, respectively [446]. Fixed amounts 
of sample DNA were mixed with scalar amounts of the multicompetitor DNA and PCR 
was performed with the 2 primer sets. The PCR reaction was run on 8% 
polyacrylamide gel and stained with ethidium bromide; the different bands 
corresponding to competitor-, AAV- or the β-globin-DNA were quantified. The 
primers used for the competitor and for the PCR amplification are listed in Online 
Table II.  
 
Chromatin immunoprecipitation (ChIP) 
The protocol for immunoprecipitation of cardiomyocyte chromatin was adapted from 
that used in ref. [447]. Day 3, day 7 and adult cardiomyocytes (approximately 
10x106 cells for each time point) were cross-linked with 11% formaldehyde for 10 
min at room temperature, followed by termination of the reaction with 125 mM 
glycine on ice. The cell pellet was washed twice in PBS, lysed in 2% NP-40 buffer 







inhibitors) to obtain purified nuclei, followed by dounce homogenization in the same 
buffer.  Lysis of the nuclei was performed using the same buffer containing 4% NP-
40 and left at 37°C for 15 min, after which micrococcal nuclease (120 U, Roche) was 
added. The reaction was stopped after 15 min with 3 mM EGTA. DNA was 
additionally sheared by sonication to an average size of DNA fragments below 0.5 
kb. Extracts were pre-cleared by 2 rounds of incubation with IgGs and agarose 
beads, followed by centrifugation at 3500 rpm for 5-10 min. The lysate (400 l) was 
then incubated with 4 g of the indicated antibody overnight at 4°C, followed by 
incubation for 4 hr with MagnaChIP Protein Protein A/G magnetic beads (Millipore). 
Beads were then washed thoroughly with RIPA150, with LiCl – containing buffer and 
with TE,  RNAse-treated for 30 min at 37°, and Proteinase K-treated for at least 2 hr 
at 56°. De-crosslinking of protein–DNA complexes was performed by an overnight 
incubation at 65°C. DNA was then subjected to by phenol–chloroform extraction, 
followed by ethanol precipitation and quantified by real time PCR using specific set 
of primers for each promoter, listed in Primer table III, previously tested to evaluate 
their amplification efficiency, and GoTaq qPCR Mater Mix (Promega). 
The following antibodies were used for ChIP: anti-H3K4me3 (ab8580, Abcam), anti-
acetyl-Histone-H3 (06-599, Millipore), anti Ezh2 (17-662, Millipore), anti-H3K27me3 
(ab6002, Abcam). For each antibody, as a negative control, ChIP was also 
performed with total IgGs. 
 
Immunofluorescence and BrdU detection 
Cells were seeded on 24-well primaria plates (~5-10x104 cells per well) and, after 3 
or 7 days of culture, were fixed with 4% paraformaldehyde (PFA) for 10 min, 
washed twice in PBS, permeabilized with PBS 1% Triton X-100 three times for 10 
min, followed by 1 hr blocking in 2% BSA (Roche) in PBS. Cells were then stained 
overnight at 4°C with primary antibodies diluted in blocking buffer. Cells were 







antibodies. Three more washes in PBS 0.2% Tween 20 were performed and then 
DAPI (Vectashield) or Hoechst 33342 (Life Technologies) were used to stain DNA. In 
the case of BrdU pulse labeling (10 μM for 20 hours for neonatal, 48 hours for adult 
cardiomyocytes), following cells permeabilization, DNA denaturation was performed 
incubating 10 min in 1N HCl on ice and 20 min in 2N HCl at 37°C. To neutralize DNA 
denaturation, cells were incubated with 0.1 M sodium-borate buffer pH 8.4 12 min at 
room temperature, then washed three times with PBS 1% Triton X-100. After the 
neutralization step, the immunofluorescence staining continued as described before 
with the blocking.  
The following were used as primary antibodies: anti--sarcomeric actinin (ab9465, 
1:250,  Abcam), anti-GFP (A6455, 1:200, Invitrogen), anti-BrdU (ab6326, 1:100, 
Abcam), anti-histone H3 phosphorylated at serine 10 (06-570, 1:100, Millipore), 
anti-Aurora B kinase (A5102, 1:100, Sigma), anti Ki-67 (PSX1028, 1:100, Monosan).  
The following were used as secondary antibodies: goat anti-mouse conjugated to 
Alexa Fluor 488 (1:500, Molecular Probes), goat anti-rat conjugated to Alexa Fluor 
555 (1:500, Molecular Probes), donkey anti-rabbit conjugated to Alexa Fluor 594 
(1:500, Molecular Probes). 
Image acquisition was performed using an ImageXpress Micro automated high-
content screening fluorescence microscope or by manual acquisition of 10 
fields/slide, and by counting in a double blinded way, scoring the number of BrdU+, 
Ki47+, PH3+ or Aurora B+ cardiomyocytes, over the total number of -actinin+ 
cells. 
 
Myocardial infarction, echocardiography analysis and AAV in vivo 
transduction 
Myocardial infarction was produced in adult female CD1 mice (8–12 weeks old), by 
permanent left anterior descending (LAD) coronary artery ligation. Briefly, mice were 







intubated and placed on a rodent ventilator. Body temperature was maintained at 
37°C on a heating pad. The beating heart was accessed via a left thoracotomy. After 
removing the pericardium, a descending branch of the LAD coronary artery was 
visualized with a stereomicroscope (Leica) and occluded with a nylon suture. 
Ligation was confirmed by the whitening of a region of the left ventricle, 
immediately post-ligation. Recombinant AAV vectors, at a dose of 1×1011 viral 
genome particles per animal, were injected immediately after LAD ligation into the 
myocardium bordering the infarct zone (single injection), using an insulin syringe 
with incorporated 30-gauge needle. The chest was closed, and the animals moved 
to a prone position until the occurrence of spontaneous breathing. To evaluate left 
ventricular function and dimensions, transthoracic two-dimensional 
echocardiography was performed on mice sedated with 5% isoflurane at 7, 14, 30 
and 60 days after myocardial infarction, using a Visual Sonics Vevo 770 Ultrasound 
(Visual Sonics) equipped with a 30-MHz linear array transducer. M-mode tracings in 
parasternal short axis view were used to measure left ventricular anterior and 
posterior wall thickness and left ventricular internal diameter at end-systole and end-
diastole, which were used to calculate left ventricular fractional shortening and 
ejection fraction.  
 
Heart collection and histological analysis 
Heart samples were collected at days 7, 14, 30 and 60 days after myocardial 
infarction. Animals were anaesthetized with 5% isoflurane and then killed by 
injection of 10% KCl, to stop the heart at diastole. The heart was excised, briefly 
washed in PBS, fixed in 10% formalin at room temperature, embedded in paraffin 
and further processed for histology staining, or slowly frozen using isopentane/liquid 
nitrogen and stored at −80°C until processed for genomic DNA or RNA extraction. 
Masson’s trichrome stainings were performed according to standard procedures, and 
analyzed for regular morphology and extent of fibrosis. Infarct size was measured as 







Production, purification and characterization of rAAV vectors 
All the AAV vectors used in this study were generated by the AAV Vector Unit (AVU) 
at ICGEB Trieste (http://www.icgeb.org/avu-core-facility.html) as described 
previously [448]. In brief, infectious AAV6 or AAV9 vector particles were generated 
in HEK293 cells by cotransfecting each vector plasmid together with the packaging 
plasmid/s expressing AAV and adenovirus helper functions, pDP6 (PlasmidFactory) 
for AAV6; p5E18 [449] plus helper plasmid (pHELPER; Stratagene) for AAV9. Viral 
stocks were obtained by CsCl2 gradient centrifugation; rAAV titers, determined by 
measuring the copy number of viral genomes in pooled, dialyzed gradient fractions, 
as described previously [450] were in the range of 1x1012 to 1x1013 genome copies 
per milliliter. 
 
In vitro AAV transduction of cardiomyocytes 
Cardiomyocytes were transduced with AAV6-EGFP, AAV6-Control, AAV6-sJ1 or 
AAV6-N1ICD contextually to plating of neonatal cardiomyocytes, at a m.o.i. of 1x104 
vg/cell. Adult cardiomyocytes were transduced the day after plating with AAV6-
EGFP, AAV6-Control, AAV6-miR-199a, AAV6-miR-590, AAV6-N1ICD,  AAV6-sJ1 at a 
m.o.i of 1x104 vg/cell. 
 
Bisulfite sequencing 
Genomic DNA was extracted from day 3, day 7 and adult cardiomyocytes in culture 
using DNeasy Blood and Tissue Kit (Qiagen). Genomic DNA (1 µg) of each sample 
was treated for DNA conversion with sodium bisulfite using EpiTect Bisulfite Kit 
(Qiagen) according to the manufacturer’s instruction. Promoter sequences were 
analyzed with using Methyl Primer Express Software v1.0 (Applied biosystems) to 
predict CpG islands. Primer sequences were designed using the same software and 
are listed in Online Table IV. Each primer set was tested to optimize PCR conditions. 







bromide and then purified from the gel using Wizard SV Gel and PCR Clean-up 
system kit (Promega). The purified DNA was cloned into TOPO T/A cloning kit 
(Invitrogen). Eight randomly picked clones were sequenced and analyzed using BiQ 
analyzer software [451].  
 
Statistical Analysis 
All data are presented as mean±SEM. Statistical analysis was performed using Prism 
Software (GraphPad), using 1-way ANOVA followed by Bonferroni post hoc test for 












Table I. Primers used to analyze gene expression levels.  
Notch1 Forward GTGCCTGCCCTTTGAGTCTT 
Reverse GCGATAGGAGCCAATCTCATTG 
Hes1 Forward GCACCTCCGGAACCTGCAGCG 
Reverse GCAGCCGAGTGCGCACCTCGGTG 
Hey1 Forward AAAGACGGAGAGGCATCATCG 
Reverse GCAGTGTGCAGCATTTTCAGG 
Hey2 Forward AGCCCCCATTAACAAGCATTT 
Reverse TAAGCTAGGGCTCACCAGAGG 
Cyclin D1 Forward AGATTGTGCCATCCATGC 
Reverse CGGATGATCTGCTTGTTC  
Ezh2 Forward TTGCTAAGAGAGCTATCCAGA 
Reverse CTGGCTGTATCTGTAATCAAA 
sJ1 transgene Forward ATTTCTGCTGAAGATATAGCCC 
 Reverse CTCCATTTCATTCAAGTCCTC 
N1ICD transgene Forward AGCAAGGAAGCTAAGGACC 
Reverse CTCCATTTCATTCAAGTCCTC 
HPRT Forward CAGTCAACGGGGGACATAAA 







able II. Primers used for competitive PCR quantification of AAV 
transduction levels. 
Primers for competitor construction 
CMV-β-globin Forward CGTCAATGGGTGGAGTATTTGATAACTGCCTTTAACGATG 
Reverse TGACGTCAATGGGGTGGAGAAGCAGCAATTCTGAGTAGAG 
Primers for competitive PCR analysis 
CMV Forward CGTCAATGGGTGGAGTATTT 
Reverse TGACGTCAATGGGGTGGAGA 
β-globin Forward GATAACTGCCTTTAACGATG 
Reverse AGCAGCAATTCTGAGTAGAG 
 
Table III. Primers used for chromatin immunoprecipitation. 








Set 1 Forward ACCAACTCCCTTGTCTCCG 
Reverse CTCCTCTGCCACTCTCTACCTCTT 
Set 2 Forward TGTGGGAAAGAAAGTTTGGGAAG 
Reverse GCTCCAGATCCAGTGTGATCCG 










Set 1 Forward CGACGTCACACACGCTCACT 
Reverse GATCTCTCCCGCCAAGTTTCT 




Set 1 Forward TTTTCTCTGCCCGGCTTTG 
Reverse AACTCCCCTGTAGTCCGAGTGA 
Set 2 Forward GCGAGCCATGCTTAAGACTGA 
Reverse AATCTCCCTCTGCACGCACTT 
GAPDH  Set 1 Forward TTCCCTGAGTCCTATCCTGG 
Reverse CTGAGATTGTCCCGCCGAG 
 
Table IV. Primers used for bisulfite sequencing. 
Notch1 
 
Set A Forward TTAGGGTAGAGTTGGTTTTTGG 
Reverse ACCCTTACTCCCCTTATAACC 












Set B Forward AAGTTGGGTAGTTAGGTTGGA 
Reverse CAATAACCTAAACCCCTCAATT 
Hey1 Set A Forward GGATAGATTGGGTTTTTTTTAGG 
  Reverse AACAATCCTTCAAAACTTCTCAA 
 Set B Forward TTTTATTTTTGGGAAGGGG 
  Reverse TCAAAACCTTCCTACACTCAAA 
Hey2 Set A Forward TATATTTGAGAAGTTGGAGGAATG 
  Reverse ACCAAACCCTCAAAAAATTTTA 
Cyclin D1 Set A Forward GAGTGGGTTTAGGGTAATTTAGG 
  Reverse ACCAAAATTCCAAAAAAAAAAA 
 Set B Forward TGGGTAAGTGGTTTTTTGTTTT 
  Reverse CCCCATCTAAAAAACCCTACTT 
 Set C Forward AGGTTAAGGTTTTTAGGTTTGG 
  Reverse CCAAAATAAATCCCTAAACCTATT 
 Set D Forward TTTTGAGTTGTTGTTGAGATT 
  Reverse AAAATACAAAAACACCCTATACTTAA 
GAPDH 
 








Set B Forward GGTTGGGGTTTTTTTTTTTAT 
Reverse CTACCATCCATCACCTAACCTA 
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